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THE ROLE AND REGULATION OF INHIBITOR OF KAPPA B KINASE (IκK) 
IN THE IMPAIRED MONOCYTE RESPONSE 
Norman J.Galbraith 
November 10th, 2016 
 Trauma, major surgery and systemic infection can lead to a 
subsequent immunosuppressed state which can predispose patients to 
nosocomial infection and death. Approximately a sixth of patients will have 
impaired monocyte function, as determined by decreased HLA-DR expression 
or decreased TNF-α production in response to ex-vivo lipopolysaccharide 
(LPS) stimulation. This project aimed to develop an in-vitro model of impaired 
monocyte function using isolated monocytes from healthy volunteers, to study 
the effect of monocyte impairment on IκK signaling, and determine the role of 
IκK in the impaired monocyte response. These studies have provided the 
following results: 
1. Monocytes treated with low dose LPS (10 ng/mL) exposure exhibit an 
impaired inflammatory response to a subsequent 100 ng/mL LPS 
challenge. Levels of TNF-α and IL-10 production, as well as monocyte 
HLA-DR expression, were decreased in the impaired monocyte 




2. Impaired monocytes that exhibited this impaired response were found 
to have decreased NFκB activation. In addition, while total levels of 
IκK-α and IκK-β were similar between naïve and impaired conditions, 
decreased IκK phosphorylation was observed in the impaired 
monocyte.  
3. Loss of IκK function studies using IκK-16 (a specific IκK inhibitor) 
showed that decreases in both TNF-α and IL-10 production were 
attributable to decreased IκK activation, demonstrating a causal 
relationship between IκK function and the monocyte cytokine response. 
However, HLA-DR expression was not dependent on IκK function, 
suggesting that other signaling pathways may also be altered in 
monocyte impairment that may affect HLA-DR expression.  
4. The impaired monocyte phenotype also results in decreased 
chemokine production (such as MCP-1 and IP-10) and growth factor 
secretion (such as GM-CSF). 
 
Our data highlight the importance of IκK function in the host defense response 
to infective stimuli, but also demonstrate the effects of negative feedback 
regulation following a primary stimulus. Excessive IκK stimulation, or indeed 
suppression of IκK activity, is likely to be detrimental to the surgical patient. 
Future studies of IκK function in the surgical patient, as well as translating 
potential therapies to modulate the IκK pathway, could ameliorate monocyte 
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Major insults to the body, such as trauma, surgery or infection, can lead to a 
complex and sometimes harmful inflammatory response. The systemic 
release of DAMPs and PAMPs stimulate toll-like receptors to cause an initial 
upregulation of pro-inflammatory cytokines which is met with a downregulation 
of antigen presenting proteins 1. A loss of this fine balance can result in 
impaired monocyte function which is typified by decreased cytokine 
production (e.g. tumor-necrosis factor alpha (TNF-α)) and decreased HLA-DR 
expression 2,3. Monocyte impairment, which is seen in approximately a sixth of 
patients after such an insult, has repeatedly predicted infective complications 
and mortality 4.  
 The pathophysiological response underpinning this form of 
immunosuppression is complex and poorly understood (Figure 1). The 
commonly held belief is that as a result of the initial stimulation, such as from 
lipopolysaccharide (LPS), negative feedback molecules increase which 
inhibits toll-like receptor signaling, thus preventing the propagation of any 
potential responses from subsequent stimuli 5. Numerous observations from 
clinical studies and from animal and in-vitro models suggest that important 
intracellular inflammatory signaling pathways such as nuclear factor kappa-B 
(NFκB) are subsequently suppressed, resulting in a decreased cytokine 




Due to such an incomplete understanding of how host defenses respond to an 
endotoxin challenge, there are no early, reliable validated markers for 
identifying and predicting patients with monocyte impairment who are at risk 
of complications at the time of writing 8. Furthermore, there are no clinically 
proven adjunctive immune therapies to improve mortality by augmentation of 
monocyte function in this subset of surgical patients 9.  
The purpose of this work is to develop a model of impaired monocyte function 
in order to understand the changes in inflammatory signaling pathways that 
result in a suppressed monocyte inflammatory response, and specifically the 
role and regulation of Inhibitor of Kappa-B Kinase (IκK), a critical link between 


























































Legend to Figure 1.  
 
Surgical insults such as trauma, major infection and  surgery itself leads to 
poorly understood pro-inflammatory and compensatory anti-inflammatory 
mechanisms. Approximately a sixth of patients will develop impaired 
monocyte function. This immunopathology is a contributory factor to the death 
of some surgical patients, and remains a potentially modifiable aspect of 
surgical care. Challenges remain in defining which patient, which adjuvant to 
give, when and for how long to deliver it. A better understanding of this 
complex immune response could help answer these questions.   










Significant insults to the body such as trauma, major surgery and overt sepsis 
of other origins are associated with the release of danger associated 
molecular patterns and/or pathogen associated molecular patterns. In the 
surgical patient, these can range from gram negative bacterial of enteric origin 
to intracellular proteins and mitochondrial DNA from cell necrosis as a result 
of major trauma. These molecules act as agonists to numerous receptors, 
such as toll-like receptors, expressed on the surface of circulating and fixed 
leukocytes. Systemic release of signaling molecules, including cytokines and 
acute phase proteins lead the systemic inflammatory response with a 
subsequent cascade of host defense dysregulation. If this phase is excessive 
or prolonged, it is thought by some to lead to harmful consequences, including 
multi-organ failure and death. The traditionally taught tri-phasic model of 
death following trauma describes many patients who survive the initial insult 
then suffer later infections in a setting of immune suppression, engendering 
the term “immunoparalysis” 11-14. This chapter aims to give an overview of 
what we believe to be a central component of this process: monocyte 




groups is identified by the first and/or senior author of the reference. Table 1 




Table 1. List of abbreviations. 
A20 See TNFAIP MKP1 MAPK phosphatase-1 
BCL B-cell CLL lymphoma MyD88 Myeloid differentiation primary 
response gene 88 
CaCP29 Monoclonal antibody targeting the 
complement cascade 
NEMO NFκB essential modulator  
CCL Chemokine (C-C motif) ligand NFκB Nuclear factor kappa-light-chain 
enhancer of activated B cells 
CD 
(14/16) 
Cluster differentiation NK cells Natural killer cells 
CLP Cecal ligation and puncture NOD Nucleotide-binding oligomerization 
domain  
CREB cyclic AMP responsive element binding 
protein 
P65 A subunit of the NFκB complex 
CXCL Chemokine (C-X-C motif) ligand PAMP Pathogen associated molecular 
patterns 
DAMP Danger associated molecular patterns PBMC Peripheral blood mononuclear cells 
ELISA Enzyme linked immunosorbent assay PD-1 Programmed cell death 1 
G-CSF Granulocyte colony stimulating factor PD-L1 Programmed cell death ligand 1 
GAPDH Glyceraldehyde 3-phosphate 
dehydrogenase 
  
GM-CSF Granulocyte-macrophage stimulating factor Poly (I:C) Polyinosinic:polycytidylic acid 
GUSB Glucuronidase Beta   
HLA-DR Human leukocyte antigen DR PPAR Peroxisome proliferation-activated 
receptor 
HMGB1 High mobility group box 1   
HRPT Hypoxanthine Phosphoribosyltransferase RAGE receptor for advanced glycation end-
products 
ICU Intensive care unit RAW 264.7 Name of a commonly used murine 
macrophage cell line 
IFN Interferon RCT Randomized controlled trial 
IL (1, 6, 
10, 12) 
Interleukin RNA  Ribonucleic acid 
IRAK IL-1β receptor associated kinase ROI/ROS Reactive oxygen 
intermediates/species  
IRF Interferon regulatory factor SOCS Suppressor of cytokine signaling 
IκB Inhibitor of κB STAT Signal transducer and activator of 
transcription 
IκK Inhibitor of κB kinase TAK1 Transforming growth factor beta-
activating kinase 1 
JAK Janus kinase TCR T-cell receptor 
LPS  Lipopolysaccharide TH (1/2) T-helper 
LTA Lipoteichoic acid THP1 & 
U937 
Names of commonly used human 
monocytic cell lines 
MAPK Mitogen-activated protein kinase THR Total hip replacement  
MCP-1 Monocyte chemotactic protein-1 TLR Toll-like receptor 
MD-2 Lymphocyte antigen 96 TNFAIP Tumor necrosis factor alpha inducible 
protein 
MDP Muramyl dipeptide TNF-α Tumor necrosis factor alpha 
MHC Major histocompatibility complex TRAF6 Tumor necrosis factor receptor 
associated factor 
MIG Monokine inducible by interferon-γ TRIF Toll/IL-1 receptor domain-containing 


















Outcomes are labeled as an uncomplicated recovery (O), survivors with post-
traumatic infection (□) and non-survivors (∆). Note the patient trajectory 
between groups becomes apparent only by day 4-6 after injury, based on this 
marker.  





Systematic observations of host defense mechanisms in ill patients 
prompted the recognition of the importance of the impaired monocyte, 
contrary to their null hypothesis 4. Specifically, a subset of approximately 15% 
of patients exhibited subnormal monocyte function and were at higher risk of 
developing infection and of death 15. This is illustrated in Figure 2, where 
differences in monocyte HLA-DR expression, a cell surface marker, become 
increasingly predictive of a patients outcome after days 4-6 following major 
trauma. 
The ultimate goal for laboratory and clinical investigators is not just to 
identify such “high risk” patients, but also to augment host defenses. This 
principle is illustrated in Figure 3, where the addition of muramyl dipeptide 
(MDP) in a rat model of a contaminated wound promotes containment, as 
opposed to permissive progression to bacteremia and subsequent systemic 
deleterious consequences 16. 
The central factor that determines a patient’s fate following a major 
insult remains unclear. In a group of patients given the same equivalent insult, 
many will be “aces” and survive, but a subset will be “dogs” and not survive 
(Fry DE, unpublished). Firstly, genetic predisposition can lead to subnormal 
host defenses. Secondly, the heterogeneous nature of an insult and its 
severity can also be decisive and thirdly, epigenetic changes, such as in 
microRNA (miRNA), may significantly result in post-translational modification 
of important pro- and anti-inflammatory signaling. Finally, prompt and attentive 
supportive care with timely surgical intervention and precise non-operative 







































































































Legend to Figure 3.  
 
Infection in skeletal muscle is contained better by MDP (●) than by placebo 
(O). As time passes from 6 hours after contamination in A, note MDP 
produces constant levels of localized bacteria where placebo treated animals 
experienced escape of bacteria into blood by 48 hours (C). This experiment 
exemplifies the potential clinical benefit from immune enhancement.  





b. The role of the healthy monocyte  
The monocyte is central to the innate immune system in the surgical patient. 
Its key roles are cytokine production, antigen presentation, and phagocytosis 
(Figure 4). Early recognition of PAMPs & DAMPs from invading microbes and 
damaged tissue activate monocytes through surface receptors such as 
extracellular toll like receptors, and intracellular receptors such as NOD-like 
receptors, RAGE receptors and certain toll-like receptors.  
This leads to the infiltration of neutrophils, traditionally the first 
leukocyte on the scene. These polymorphonuclear cells have the most potent 
phagocytic ability, which are followed by infiltrating circulating monocytes due 
to chemokines. These can differentiate and thus expand the numbers of 
tissue macrophages. Throughout this process, monocytes secrete cytokines 
which have systemic consequences on remote organs such as the liver, 
gastrointestinal system and endothelium, especially that in lung parenchyma. 
Furthermore, this cell-to-cell communication leads to a crucial link to the 
adaptive immune system through complex T-cell interactions. The monocyte, 
and other antigen presenting cells, allow fragments of invading bacteria, such 
as LPS, to be processed in vesicles and externalized through MHC II 
complexes, such as HLA-DR, that bind to T-cell receptors  on receptive T-
cells. This bi-directional interaction can also further promote 
monocyte/macrophage activation through endogenous IFN-γ from T-cells and 
natural killer cells. However, in patients with a subnormal immune system or 
persistent antigen stimulation, this process can be blunted through the 





 Figure 4. Basic monocyte functions.  
 
The monocyte is a highly important circulating leukocyte which links the innate 
to adaptive immune systems. Its primary functions include cytokine production 
(such as TNF-α, IL-10, IL-1β and IL-12), antigen presentation (through major 
histocompatibility complexes such as HLA-DR) and phagocytosis. Impairment 
of the first two functions have been correlated with poor outcomes in surgical 
patients, thus we believe that they are the two most clinically relevant 
functions to study.  





Invading microbes initially evoke a T-helper (Th) 1 response from CD4 T-cells. 
In this type of response, T-cells secrete IFN-γ and IL-2, further promoting and 
activating monocytes and macrophages in a pro-inflammatory manner. While 
this response is linked to the “M1” pro-inflammatory macrophage, the 
alternative Th2 response (associated with allergens and Helminths) secretes 
IL-10 and IL-4 promoting the “M2” anti-inflammatory macrophage.  
Cytokines are secreted proteins, acting in a paracrine manner to influence 
the differentiation and response of surrounding immune cells. Of a multitude 
of cytokines that monocytes secrete, the most clinically studied (and their 
function) include; 
 Pro-inflammatory cytokines  
o TNF-α - promotes inflammation and endothelial activation 
o IL-6 - acute phase response promoting fever and T/B cell growth 
o IL-1β - fever, activation of monocytes, macrophages, T-cell 
activation 
 Anti-inflammatory cytokines 
o  IL-10 - suppresses monocyte function 
Cytokines influencing monocyte behavior are discussed below. While 
monocytes do phagocytize bacterial pathogens, defects in its phagocytic 
ability appearing to be less important in the fate of the surgical patient when 
compared to altered cytokine release and antigen presentation. 




1. The classical monocyte accounts for the vast majority of 
circulating monocytes, expressing high CD14, medium HLA-DR 
expression, but no CD16 expression (CD14++ CD16-). These cells 
produce both TNF-α and IL-10.  
2. Non-classical monocytes express lower levels of CD14, but high 
CD16 and HLA-DR (CD14+CD16++). They secrete TNF-α but not 
IL-10.  
3. Finally intermediate monocytes express high levels of CD14, but 
low CD16. (CD14++ CD16+). This subset has gained increasing 
recognition over the last 5 years and is noted to have increased IL-
10 production. Interestingly, they have been correlated with sepsis, 
myocardial infarction and early, but not metastatic colorectal cancer 
18.  
It is worth noting that monocytes, macrophages and dendritic cells are all 
myeloid derived with largely similar expression of toll-like receptors. While this 
body of work focuses on the monocyte, many of the concepts discussed 





c. Clinical scenarios and the monocyte response  
Major trauma & burns 
As post-traumatic and indeed all critical care improved, it became apparent 
that some survivors of major trauma were susceptible to later infection. 
Evidence grew that this may be a consequence of depressed host defenses 
19.  Our systematic study of various facets of the innate immune system 
revealed that monocyte antigen presenting ability was highly predictive of 
infection following major trauma 4. It was apparent that not only absolute 
monocyte HLA-DR expression, but the ability to up-regulate this MHC II 
surface marker in response to endotoxin exposure was also predictive of 
morbidity and mortality. Since then, studies focusing on HLA-DR expression 
as a marker of monocyte function demonstrate that this remains consistently 
predictive for poor outcomes following trauma as well as folowing burns 
(Table 2 2,4,15,20-33). Increasingly, CD14+ HLA-DR- cells are described as 
“myeloid derived suppressor cells” and this phenotype has also been 
observed in the orthopedic patient following intramedullary nailing following 
fracture of the tibia 34. 
The revolution of cytokine related research prompted another aspect of 
monocyte function to be examined – ex-vivo cytokine production in response 
to endotoxin exposure, both in “whole blood” and in isolated peripheral blood 
mononuclear cells. In general, early high IL-6 production and subsequent 
lower TNF-α production appears to characterize this dysregulation 35. 
Furthermore, the role of the anti-inflammatory IL-10 has long been debated, 










Table 2. Salient observations from selected papers relating monocyte function 


















 HLA-DR Burns Septic shock Crit Care, 2007 
LAHIRI 
22







Ann. Surg, 2015 
POLK 
4
 HLA-DR Trauma Mortality Ann. Surg, 1986 
CHEADLE 
23
 HLA-DR Trauma Infection Am. J. Surg, 1991 
PLODER 
2






















 STAT3, CREB, 
NFκB 
Elective THR Recovery, 
function, pain 









Ann. Surg. 2015 
LYONS 
27
 IL-10 Trauma Septic events Ann. Surg. 1997 
STENSBALLE 
28






















 IL-6 Trauma *review Ann. Surg. 1996 
CHERON
32
 IL-6, HLA-DR Trauma Sepsis PloS One, 2012 
GUIGNANT 
33
 PD-L1 Septic shock Secondary 
infection 
Mortality 





Findings of the Inflammation and the Host Response to Injury Large Scale 
Collaborative Research Program relating to monocyte function 
A highly funded multi-center project, the “Glue Grant”, aimed to take a 
‘systems approach’ to the host inflammatory response to trauma and burns, 
primarily focusing on gene expression studies1. This design was to lessen the 
reductionist approach of multiple groups focusing on one single aspect of the 
host defenses which was seen as likely to fail given the redundancy of the 
immune system. It is worth noting that the patients studied were critically ill; 
generally being hypotensive, having received blood products, and 
demonstrating some form of organ dysfunction. Selected papers from this 
effort pertaining to monocyte impairment are discussed below. 
Xaio et al 1 sequentially studied peripheral blood leukocyte genome 
wide expression of mRNA in 167 severely injured trauma patients up to 28 
days after injury. In addition, patients with greater than 20% burns and healthy 
individuals were analyzed. A change in over 80% of gene expression, termed 
a “genomic storm”, was observed. This response to trauma was non-specific, 
with 98% of the same genomic changes seen in burn patients, and 88% of 
that seen in experimental endotoxemia. A complicated recovery was 
associated with the up-regulation of innate immunity genes including IL-6 and 
IL-10, with a simultaneous down-regulation of adaptive immunity genes such 
as those relating to antigen presentation. Importantly, they demonstrated that 
contrary to conventional thinking, leukocyte genomic responses of both pro- 
and anti-inflammatory pathways were simultaneous, rather than a so-called 
                                                          
1
 The Glue Grant: Inflammatory and the host response to injury (PI: Tompkins RG). National Institute 




“second hit” or insult causing the anti-inflammatory component 1. Laudanski et 
al examined both monocyte and T-cell pathways of 18 trauma patients using 
high throughput screening of gene expression 37. Interestingly, the response 
to trauma was very specific to the cell type, with only 11% of pathways 
common to both monocytes and T-cells, such as a down-regulation of the 
transcription factor NFκB. This further demonstrated a down-regulation of 
antigen presentation genes such as HLA-DR and CD86, with an increase in 
monocyte negative co-stimulatory genes such as PD-L2. In keeping with the 
down-regulation of antigen presenting pathways in monocytes, T-cells 
demonstrated molecular choreography with reciprocal increases in genes 
relating to apoptosis and anergy 37. 
In a more recent study from the same dataset, 8% of the 1595 subjects 
included had proven gram negative bacteremia. These 127 patients had an 
increased risk of mortality (21%), compared with those without infection 
(11%). Gene expression of these patients was compared with those who did 
not contract infection, showing certain pro-inflammatory pathways to be 
similar 12 hours following injury. However, at 96 hours after injury IL-1β and 
IL-2RB were markedly decreased in those who died. Furthermore, expression 
of genes relating to monocytes such as HLA-DR and CD163 was similarly 
increased at 12 hours after injury, but at 96 hours a significant decrease in 
gene expression were apparent in the group who went on to develop gram 
negative bacteremia 38. This project has increased our understanding of the 
pathways involved in host defenses following major trauma. Perhaps not 
surprisingly given the recognition of such complexity, the surgeon remains ill-




Inflammatory networks following trauma 
Since the prior project came to an end, other groups have adopted a ‘systems 
biology’ approach to better understand inflammatory networks after major 
trauma. The Pittsburgh group studied 472 survivors of blunt trauma for 
circulating plasma cytokines and chemokines. The findings were analyzed 
using emerging computational methods reflecting that various patterns were 
demonstrable in the first 24 hours, much earlier than the diagnosis of infection 
made 7 days after injury. Serum markers that were significantly elevated in 
patients who later developed infection include HMGB1, IL-6 and IL-1RA, to 
name a few. Dynamic Bayesian networks inferred that IL-6 was affected by 
various chemokines, such as MCP-1 and MIG 39,40. 
Major elective surgery 
Major abdominal operations, and general anesthesia, have long been 
associated with post-operative immunosuppression. Factors such as 
increasing age, prevalence of diabetes mellitus and immunosuppressive 
medications (neoadjuvant chemotherapy, glucocorticoids and monoclonal 
antibodies such as anti-TNF-α antibodies) increase the relevance of this 
concept today. However, the prevalence of impaired monocyte function also 
extends to the patients of neurosurgeons, transplant surgeons and cardiac 
surgeons 41-43. More recently, Albertsmeier showed that major abdominal 
surgery leads to an expansion of CD14+ HLA-DR- cells. This group of 
monocytes secreted TNF-α and IL-6, but when co-cultured with T-cells led to 
decreased T-cell IFN-γ secretion 44. Studies in the last few years have 




behavior, as discussed later. Furthermore, dysregulation of pro-inflammatory 
pathways in monocyte subsets, such as NFκB in intermediate monocytes, led 
to higher TLR and IL-6 expression that was associated with increased 
infective complications 22,26. 
Overt sepsis 
Major infection, namely severe sepsis and septic shock, is the most common 
clinical event associated with monocyte impairment. While the majority of 
studies use flow cytometry to quantify either the percentage of monocytes 
expressing HLA-DR, or mean fluorescence intensity, more recent studies 
show that gene expression of HLA-DR is also predictive of infective 
complications 21,45. Furthermore, bench to bedside studies of monocyte 
impairment reveal dysregulated gene expression patterns, including genes 
such as S100A8/9, TNFAIP6 and IRAK-M (as well as TNF-α, IL-10 and HLA-
DR)  which have been suggested to “monitor efficacy” of IFN-γ therapy 46-48.  
There has been increased interest over the past decade in the 
differential expression of negative co-stimulatory molecules in septic patients. 
This has been in part due to the recognition of T-cell anergy and apoptosis as 
a driver of immune suppression, which is also observed in some cancers 49. 
Monocyte co-stimulatory antigens such as CD86 and PD-L1 correspond to T-
cell CD28 & PD-1 respectively, which may be considered “on” and “off” 
switches in addition to the central HLA-DR–T-cell receptor  (TCR) interaction. 
The potential importance of negative co-stimulatory molecules has been 
highlighted by reported improved mortality in murine models of surgical sepsis 




increased monocyte PD-L1 as well as increased T-cell PD-1 expression in 
infected patients. In one study of 64 patients with septic shock, of which 42% 
had an abdominal source, had increased expression of monocyte PD-L1 and 
T-cell PD-1 compared to healthy controls, which was also predictive of 
secondary nosocomial infection 33. In another study of 90 critically ill surgical 
patients, blood samples within 24 hours of admission to the ICU showed 
increased monocyte PD-1 expression, correlating with APACHE II scores 52. 
In addition, certain PD-1 polymorphisms have been associated with higher 
mortality in a study of 221 patients diagnosed with sepsis or septic shock, in 
which lung infections were the most common source of infection 53. 
 
d. Patient factors influencing monocyte function  
The practicing surgeon caring for sick surgical patients may adversely 
influence monocyte function unknowingly, as summarized in Table 3 54-63. 
Experimental models have shown that protecting patients from unintentional 
hypothermia may promote the pro-inflammatory response through increased 
miRNA-155 expression and subsequent higher TNF-α and lower IL-10 
production 54. The once popular very precise glucose control in critical care 
environments may risk harmful hypoglycemic episodes, but also blunt the 
cytokine and bactericidal properties of the monocyte 55. Supplemental oxygen, 
to an inspired oxygen concentration of 80% appears to have mixed effects on 
the monocyte and in particular increases reactive oxygen species 56. The 
immunosuppressive effects of blood transfusion have been recognized for 
many years, but recent studies implicate small circulating biomolecules, such 




DR expression 58. The role of minimally invasive surgery on monocyte 
function has remained controversial 64. Recent studies have suggested that 
minimally invasive surgery, such as laparoscopic or robotic approaches, are 






Table 3. Clinical factors influencing monocyte function. 
 
Clinical factor Parameter Impact Selected references 
Temperature (hyperthermia) TNF-α Increase Billeter, FASEB, 2014 
54 





Qadan, JACS, 2010 55 








Blood Transfusion LPS induced TNF-α 
IL-6 
Decrease Muszynski, 
Transfusion, 2014 & 
2015 57,58 






Veenhof, Int. J. 
Colorec. Dis, 2011 59 







Coloproc. 2015 60 
Laparoscopic (over open liver 
resection) 
HLA-DR Increase Chopra, JSLS, 2013 61 
Laparoscopic (over open 
contaminated 
cholecystectomy) 
HLA-DR Increase Sista, WJGS, 2013 62 
Laparoscopic (better than 
open colectomy, 
independent of fast-track) 







e. Defining and studying the impaired monocyte  
Clinical studies have shown that monocyte impairment, also described as 
“endotoxin tolerance”, is not common in most surgical patients and pertains to 
only some previously unsuspected patients. Therefore, it becomes difficult to 
adequately power and fund clinical studies to examine mechanisms behind 
this pathology.  
Over the last 15 years, both in-vitro and in-vivo murine models have been 
used to study endotoxin tolerance. Endotoxin tolerance was discovered by 
Beeson, who found that repeated injection of endotoxin led to a progressively 
decreased febrile response 65. We now know that exposure to endotoxin, 
often LPS, stimulates various negative regulators to inhibit a subsequent 
response when compared to a naïve cell. This has been shown to be akin to 
the impaired monocyte response seen in the critically ill surgical patient 7. We 
consider monocyte impairment and endotoxin tolerance in monocytes to be a 
very similar phenomenon. Various studies have shown “cross-tolerance”, in 
that the same molecular mechanisms behind such impairment also occur with 
other so called “priming” agents including: 
 PAMPs/DAMPs 
o Lipoteichoic acid (TLR2) 
o Poly (I:C) (TLR3) 








o IL-10 5  
Common models include isolated primary cells such as CD14 
monocytes and PBMCs as well as cell lines such as THP1 and U937 
monocytes, and RAW 264.7 macrophages. In-vivo models expose mice to low 
dose intraperitoneal LPS, followed either by ex-vivo stimulation, or in-vivo 
cecal ligation and puncture. Human in-vivo models have used subcutaneous 
LPS, followed by ex-vivo leukocyte stimulation 66. The most accepted in-vitro 
outcome of the LPS pre-treated “impaired” cell is reduced TNF-α production 
compared to naïve cells, measured either by supernatant protein secretion by 
ELISA or gene expression of TNF-α mRNA. Other cytokines have been 
reported variably 5. Although reported less frequently, this approach is thought 
to represent monocytes with reduced antigen presenting capability 67,68. 
Pathophysiological mechanisms behind the impairment of the 
monocyte response are complex and influence various molecular pathways 
(Figure 5 5). In toll-like receptor signaling, the MyD88-dependent pathway is 
inhibited at various levels such as sMyD88 and IRAK-M that inhibits TRAF6. 
Furthermore, A20 increases and thus inhibits TRAF6 via deubiquitination. It is 
at this level that Pellino-1, a positive regulator, is decreased in impaired cells 
69. Recently monocyte impairment has also been associated with disruption of 
the interaction between IRAK1 and IκK-γ (also known as NEMO) although the 
























































Legend for Figure 5.  
 
Homeostatic mechanisms to prevent excessive inflammation and promote the 
resolution of the response are in part regulated by intracellular negative 
regulator molecules. These regulators act to suppress and downregulate the 
production and/or activation of key pro-inflammatory pathways. Note a 
number of epigenetic mechanisms that control toll-like receptor signaling 
exist, such as post-transcriptional silencing by microRNA-146a, and A20 
which promotes the deubiquintation of TRAF-6.   





The initial LPS stimulation decreases the degradation of IκB in impaired 
monocytes, which act as the “brakes” in the NFκB pathway. Therefore, there 
is decreased p65 phosphorylation and subsequent translocation to the 
nucleus, in part explaining the decreased gene expression of pro-
inflammatory cytokines.  Furthermore, the non-canonical NFκB pathway has 
been reported to be involved, with impaired cells having increased expression 
of RelB, c-Jun and the homodimer of p50-p50 of NFκB rather than the more 
commonly expressed p-65-p50 heterodimer 71. 
The MAPK pathway is also dysregulated, with evidence of decreased 
TAK1 phosphorylation in impaired cells, which leads to decreased MAPK p38 
phosphorylation 70. Other known negative regulators that are not discussed 
here include SOCS1, SOCS3, BCL3, PPAR-γ and CREB  5. 
MicroRNAs (miRNAs) are short, non-coding RNA molecules involved in 
post-transcriptional regulation of gene expression.  Various miRNAs are 
dysregulated in monocyte impairment, with miRNA-146a being the most 
studied. This increases as a physiological response to LPS, and subsequently 
inhibits TRAF6 and IRAK1. Murine knock-out or antagomiR-mediated 
inhibition of miRNA-146a rescues the impaired response. Further miRNAs 
shown to influence monocyte impairment include let-7a, miR-223, -221, -9, -
150 and -1325. 
However, despite the manipulation of numerous negative regulators 
demonstrated in-vitro to improve the monocyte response, none of these are 
known to have gained scientific momentum or reached the bedside. Such 




Furthermore, murine studies of sepsis, such as those using models of cecal 
ligation and puncture (CLP), have for many years raised unfulfilled hope in 
potential immunotherapies for the impaired monocyte, but have not yet 
translated to clinical success. One reason for this might be that not all of the 
immune system is conserved from mice to man. Murine models are overtly 
oversimplified - there are no additional variables such as blood transfusion, 
fluid resuscitation, antibiotic therapy and other co-morbidity. Finally, genetic 
variations in patients are obviously not represented in the narrow pool of mice 
and cell lines. 
 
f. Inhibitor of κB Kinase (IκK) – the known and unknowns governing 
the gateway from TLR to NFκB 
 
IκK is an intracellular protein complex involved in the canonical pathway of the 
NFκB pro-inflammatory signaling pathway.  The complex is made up primarily 
of 3 subunits; IκK-α, IκK-β and IκK-γ (also known as NEMO) (Figure 6) .  The 
first two subunits are considered catalytic subunits which are primarily 
involved in the propagation of a response from upstream signals, often 
secondary to stimulation by IL-1β, TNF-α or a TLR ligand such as LPS.  
  IκK-α  (also known as IκK-1 or CHUK) is involved in both the 
canonical pathway with IκK-β, but also plays a role in the non-canonical 
signaling pathway in response to ligands such as lymphotoxin B, which 
activates NFκB inducing kinase (NIK) to phosphorylate IκK-α. This in turn 




 IκK-β (IκK2) is considered the main active subunit in the canonical 
NFκB pathway. This subunit is bound to IκK-α, and through activation of a 
variety of upstream pathways (most commonly through MyD88/TRAF-6/TAK-
1) both the α and β subunits can be phosphorylated. It should be noted that 
upstream input signals for IκK phosphorylation are extraordinarily complex 
with various levels of regulation from related kinases and phosphatases. It 
has been shown that IκK phosphorylation is not dependent on TAK-1 alone, 
with over 15 potential input sources 72,73 Phosphorylation of the α & -β 
subunits leads to a conformational change allowing the complex to undertake 
its primary role of phosphorylating IκB, as its name suggests. IκB 
phosphorylation is the critical step in NFκB activation. IκB act as the “brakes” 
in this pathway, and once phosphorylation occurs IκB then undergoes 
ubiquitination and subsequent proteosomal degradation. This allows the main 
active NFκB complex comprising of the p65 (RelA) and p50 heterodimer to be 
“released”, where it translocates from the cytoplasm to the nucleus. Here, 
NFκB promotes the transcription of pro-inflammatory genes such as TNF-α, 
IL-10, IL-6 among many others.  
  The IκK-γ (NEMO) subunit is considered a regulatory unit, rather 
than a catalytic unit, meaning that  it chaperones the α and β subunits from 
TRAF-6 and TAK-1 towards the NFκB subunit following activation. A fourth 
IκK subunit, IκK-ε (Also termed IκK-i) exists but this subunit is part of a 
separate signaling cascade, along with TBK1, that activates the transcription 
factor IRF3 to promote type I interferon production. Experimental evidence 
suggests that IκK-β and IκK-γ are critical for NFκB activation in order to mount 




Figure 6. Inhibitor of κB Kinase (IκK) pathway in the activation of NFκB 
  
The classical pathway of IκK is activated by various DAMPs and PAMPs such 
as LPS. Phosphorylation of the IκK-α and/or –β subunits activates the IκK 
complex, which directly phosphorylates IκBα. This leads to the degradation of 
these “brakes” releasing the p65/p50 heterodimer (the key active canonical 
NFκB subunits) to become phosphorylated themselves and translocate the 
nucleus for the transcription of pro-inflammatory genes.  





Clinical implications of IκK 
  Numerous studies over the years have investigated the 
dysregulation of cytokines that are dependent on IκK & NFκB, such as TNF-α 
and IL-6, which are predictive of poor outcomes in surgical patients 28,31. More 
recent studies have shown that excessive early NFκB stimulation is predictive 
of mortality in CLP models and predictive of systemic inflammatory response 
syndromes (SIRS) following major elective surgery75, 76. These differences in 
the magnitude of activation may be surrogate markers for excessive early 
stimulation of IκK, upstream to NFκB in this pathway, however, few studies 
have examined IκK activation itself in surgical patients.  
  The Inflammation and the Host Response to Injury studies have 
been discussed earlier. In such high throughput genomic studies where 
thousands of mRNA levels are measured sequentially, reports did reveal 
some significant changes in IκK mRNA levels in trauma patients. Specifically, 
Laudanski et al examined cell-specific mRNA expression in monocytes and T-
cells isolated from trauma patients 37. IκK-β was downregulated and IκK-ε was 
upregulated in the monocyte when compared to healthy controls. Upstream of 
IκK, NIK was also upregulated. T-cells demonstrated a similar pattern of IκK-β 
downregulation. IκK-α was not different and IκK-γ was upregulated compared 
to healthy controls.  
  Various studies of in-vitro and in-vivo models have 
demonstrated IκK phosphorylation in response to LPS and CLP, respectively 
77. There has been increasing attention towards IκK blockers as a potential 




blocker, SAR113945, was used in a phase II trial via intra-articular injection 
for osteoarthritis in Germany (clinicaltrials.gov).  
  In 2013, Coldewey and colleagues used another IκK blocker 
(IκK-16) in a mouse model of peritonitis 78. They found that IκK-16 was 
effective in preventing the degradation of IκB, limiting inflammation and 
decreasing lung injury caused by the infection. A group from China in 2014 
found that IκK-16 was effective in reducing end organ failure in a rat model of 
ventilator-assisted lung injury 79.  
  More recently, Sordi et al used IκK-16 by intraperitoneal 
injection in a rat model of hemorrhagic shock. The phosphorylation of IκK was 
successfully inhibited, with corresponding decreases in pro-inflammatory 
cytokines. Treated rats had reduced lung injury, and also renal and hepatic 
markers of organ failure were lessened 77. In  2016, the same group reported 
the application of IκK-16 in a murine model of sepsis, using both LPS and 
CLP, with pre-existing renal impairment (by nephrectomy). This demonstrated 
improvements in sepsis-associated myocardial dysfunction 80.  
  One lesson from history tells us that the therapeutic approach to 
immune modulation should not aim to simply prevent or “turn off” inflammation 
as this may have unrecognized harmful effects. Li et al examined the effect of 
IκK inhibition on other aspects of host defenses in a mouse model of CLP 81. 
The benefits of decreased pulmonary edema were seen with IκK inhibition, 
and treatment of cultured macrophages did not negatively influence 
phagocytosis of bacteria or decrease colony forming units in blood, lung or 




  In general, IκK appears to  be a critical step in mounting a 
sufficient inflammatory response to an infective challenge. However, 
excessive stimulation appears to lead to exaggerated release of cytokines 
and downstream organ dysfunction. These undesireable consequences can 
be prevented in surgically relevant animal models of sepsis and shock, which 
makes IκK-16 an attractive therapeutic approach. However, we do not know 
how IκK function is affected in the context of monocyte impairment, where 
immune suppression is part of the pathophysiological problem. In addition, we 
do not understand the exact role of IκK in cytokine and antigen presentation 
functions, and whether the same benefits of IκK modulation will be seen when 
translating this approach to the human inflammatory response.  
  In summary, the monocyte is a master regulator of the immune 
response following major insults to the body through its important roles in 
cytokine production and antigen presentation. The functions of these roles are 
influenced by a variety of patient factors and by various clinical scenarios. 
There is a significant body of evidence that major physiological insults such as 
trauma can lead to excessive depression to the responsiveness to LPS and 
HLA-DR expression which results in an increased risk of infection and death. 
The function and role of IκK in monocyte impairment is not clear. We believe 
this complex and clinically relevant phenomenon is worthy of detailed study.  
 
 





PAST, PRESENT AND FUTURE OF AUGMENTATION OF MONOCYTE 
FUNCTION IN THE SURGICAL PATIENT 
 
a. Background  
Sepsis is a clinical condition in a patient that has changes in systemic 
parameters combined with a proven source of infection. However, the 
underlying pathophysiology occurs in response to the dissemination of 
bacteria or other PAMPs/DAMPs into the bloodstream. This stimulates toll-like 
receptors to produce an inflammatory response, governed NFκB and MAPK 
p38 pathways to promote cytokine and chemokine release that results in the 
clinical signs and symptoms that many junior physicians recognize. A very 
similar response is seen following major trauma. Through the “Surviving 
Sepsis Campaign” there has been increased prompt recognition of the early 
phases of sepsis, with the aim of early goal-directed therapy such as titrated 
fluid boluses, appropriate intravenous antibiotic administration and closer 
monitoring of hourly urine outputs and serial lactate measurements. However, 
the later phases of a major insult such as major trauma, burns, or major 
infection that may include components of immunosuppression remain 
oblivious to many clinicians. The simultaneous down-regulation of antigen 




reduced HLA-DR expression, decreased TNF-α production in response to 
lipopolysaccharide (LPS) exposure and also T-cell anergy. This phenomenon, 
discussed in the previous chapter, does not yet have as widely accepted 
corrective or adjunctive therapy, although numerous credible laboratories 
pursue the subject in their own ways.   
A major flaw in many of these studies, including our group’s previous 
work, is the failure to define what is the most appropriate threshold in the 
laboratory to define impaired monocyte function and the most meaningful 
duration of that impairment. While low monocyte HLA-DR expression is 
commonly cited as the most commonly used predictive marker of surgical 
infection, reports have been variable in part due to a lack of standardization 
between laboratories. Newer methods of calibration to calculate the number of 
HLA-DR antibodies per cell have somewhat improved upon this problem 82,83.  
Various studies have aimed to boost immune function by increasing the 
proportion of normal, activated monocytes (such as with interferon-gamma, 
GM-CSF or other agents), but this has failed thus far to consistently show a 
reduction in mortality 3,84,85. One of the biggest challenges has been in 
defining and identifying this subset of patients, which has in parallel stimulated 
the field of endotoxin tolerance research 5,7. This principle is illustrated in 
Figure 7, where the monocyte previously stimulated by LPS has a decreased 
responsiveness to a subsequent LPS challenge. The role of potential therapy 
is demonstrated in Figure 8, an in-vivo model of endotoxin tolerance. Here, 
one can see the augmentation of TNF-α production when interferon-gamma is  
given subcutaneously. This chapter aims to address the evidence and lessons 














The naïve monocyte with no previous exposure to endotoxin represents a 
healthy response to a challenge, such as LPS, with a high level of TNF-α 
production (seen in green). By comparison, the impaired monocytes with 
early, low dose exposure to LPS mount an initial response characterized by 
high TNF-α levels but then becomes refractory to a subsequent LPS 
challenge, characterized by a blunted, lower level of TNF-α levels (seen in 









This figure demonstrates human in-vivo monocyte impairment in response to 
subcutaneous LPS administration. Compared to the first LPS dose (day 1), 
there is decreased monocyte responsiveness with decreased TNF-α 
production demonstrated above, to a second dose (day 7). Note partial 
reversal with IFN-γ & GM-CSF, when given between doses.  





b. Clinical evidence for therapies: 
IFN-γ 
Polk et al, Am. J. Surg. 1992 (Trauma) 85 
IFN-γ has safely been used in humans for other clinical indications such as 
malignancy. A pilot clinical trial of 15 patients who were treated with IFN-γ 
following major trauma demonstrated increased monocyte HLA-DR 
expression, albeit in a narrowly focused study. This was followed by a larger 
prospective randomized controlled trial of 201 patients enrolled with an injury 
severity score over 20 with bacterial contamination. Recombinant IFN-γ (100 
µg) was given subcutaneously for 10 consecutive days, among 4 medical 
centers. HLA-DR expression was augmented for the duration of IFN-γ 
treatment; however, levels quickly returned to that of the placebo group after 
treatment cessation at day 10 (Figure 9). Patients were followed up to 90 
days and it was noted that a quarter of infections occurred after day 11. Fewer 
patients required an operation for infection and mortality appeared lower in 
the IFN-γ treatment group, although this was not statistically significant. Fever 
was experienced in 93% of treated patients as a side effect of therapy. The 
authors later concluded that future trials might consider administering doses 
on alternate days over a longer duration, with the aim of reducing febrile side 
effects yet extending therapy 87. Interestingly, this was a keystone of 









For the duration of treatment, the interferon-γ treated group (inverted 
triangles) benefit from increased monocyte HLA-DR expression (mean 
fluorescence intensity) compared to the placebo group (circles). However, 
note the rapid return of monocyte HLA-DR to a similar level to the placebo 
group after the final dose of the regimen (given on day 10 post-injury, see red 
arrow).   





Dries et al, Arch. Surg 1994 (Trauma) 84 
A second randomized controlled trial was undertaken in parallel, with 
416 patients across 9 centers randomized to IFN-γ or placebo. Again, severe 
trauma was the indication, but the major difference in design was that doses 
were given on alternate days, for 20 days rather than 10 days. The 
differences between this and the previous trial are discussed at length 
elsewhere 87. The major findings were that all-cause mortality was similar, but 
infection related deaths were lower in the treatment group (3% IFN-γ vs. 9% 
placebo). The authors noted an unusually high mortality rate in the placebo 
group in a single hospital that contributed this large imbalance. Interestingly, 
the treatment group did have a longer ICU stay than placebo, perhaps 
attributable to investigation of the febrile reaction to therapy. The excess 
death rates in the placebo arm in the leading enrolling institutions has not 
been solved intellectually or technically. 
Docke et al, Nature Medicine, 1997 (Sepsis) 3 
In 1997, Docke et al used IFN-γ in 9 patients diagnosed with sepsis 
and impaired monocyte function. This “monocyte deactivation” was defined as 
patients with less than 30% HLA-DR positive monocytes for 2 consecutive 
days, in the context of Bone’s criteria for sepsis 88. Therapy was continued 
until HLA-DR expression was restored for 2 consecutive days, or 8 days total. 
Therapy also boosted ex-vivo TNF-α production when compared to 26 
historical controls. This novel approach appeared to help clear infection in 8 of 
the 9 patients included. The mortality rate for the treatment group was 




conclusions on mortality. This approach of treating only patients with evidence 
of monocyte impairment was promising for larger studies. These authors 
appear not to have performed or contributed to other trials to enhance the 
power of this 9-patient trial. 
Wasserman et al, Crit Care Med, 1998 (Burns) 89 
This phase III randomized double-blinded trial compared subcutaneous 
IFN-γ in 109 burn patients compared with 107 patients receiving placebo. 
These patients had severe burns, scoring at least 7 using the abbreviated 
burn index. Therapy was started in the first 4 days after thermal injury and 
continued daily until 90 days, hospital discharge, or wound closure. IFN-γ- 
treated patients had equivalent rates of major infection and death. The 
putative benefits of therapy could have been masked by including patients 
with no evidence of monocyte impairment and the inclusion of older, severely 
burned patients, likely to die regardless of intervention.  
Nakos et al, Crit Care Med 2002 (Trauma) 90 
In 2002, Nakos et al studied mechanically ventilated trauma patients 
with a decreased alveolar macrophage HLA-DR of less than 30%, obtained 
through bronchoscopy (compromising 21 of 52 patients). Patients were 
randomized to inhaled recombinant IFN-γ (11 patients) versus placebo (10 
patients). Injury severity score was 40 and 43 respectively in these groups. 
The treatment group received inhaled IFN-γ three times a day. Investigators 
found HLA-DR expression increased from a 16.4% to 44% in the follow up 
bronchoscopy on day 3 post injury. This compared with persistence of low 




concentration in bronchoalveolar fluid and decreased rates of ventilator-
associated pneumonia compared to placebo. It is not clear whether the 
inhaled delivery allowed IFN-γ to have significant systemic effects. Mortality 
remained unchanged. This important trial needs to be repeated; the study of 
alveolar macrophages with inhaled IFN-γ “therapy” is unique. 
Schinkel et al, Shock, 2001 & Licht et al, J. Interfer. Cytoki. Res. 2003  
(Major elective surgery) 91,92 
The Faist group (both papers) screened 209 patients undergoing major 
surgery for pre-operative immunosuppression, as defined by a negative 
delayed type hypersensitivity skin test 91. Of these, 46 anergic patients (22%) 
were randomized to pre-operative parenteral IFN-γ administration (-7, -5, and 
-3 pre-operative days). Visceral, gynecological, vascular, and thoracic 
operations were included and were said to be physiologically equivalent in 
each group. There was a significant increase in peripheral monocyte HLA-DR, 
serum IL-1 and IL-8. LPS induced TNF-α was also augmented. A subsequent 
report from the same group in 2003 reported that treated patients 
demonstrated increased IL-2R levels and decreased IL-4 levels, without an 
effect on IL-10 or lymphocyte proliferation, suggesting a shift to a Th1 
phenotype. The authors cited a generally low number of infectious 
complications and were unable to demonstrate any real differences in 
morbidity and mortality.  There are many examples of bias in these trials of 
dually reported patients that could warrant repeating the trial in more depth 
and breadth, particularly to the extent that skin testing does or does not reflect 





Meisel et al, Am J Respir Crit Care Med, 2009 (Sepsis) 93 
This prospective, randomized double blinded trial using granulocyte-
macrophage colony stimulating factor (GM-CSF) was undertaken in very ill 
patients, requiring the presence of severe sepsis or septic shock for inclusion. 
More specifically, patients were required to have depressed monocyte HLA-
DR expression for two consecutive days. This yielded 38 patients from a total 
of 135 who were screened for impaired monocyte function. Pneumonia was 
the leading cause of sepsis, accounting for 60% of the 38 patients, while 
peritonitis was responsible for 30%. Following 8 days of treatment, all 19 
patients in the treatment arm demonstrated increased monocyte HLA-DR 
expression, as well as restored ex-vivo TNF-α secretion. Furthermore, 
increased T-cell and monocyte counts increased, accompanied by a decrease 
in IL-10. Such patients had shorter time of ventilation and shorter ICU stays, 
however mortality was 16% in the GM-CSF group vs. 21% in the placebo 
group, this did not reach statistical significance.  
Leentjens et al, Am J Resp Crit Care Med, 2012(Experimental endotoxemia)86 
Leentjens et al successfully induced impaired monocyte function in 
healthy volunteers with low dose intravenous LPS. Eighteen males were 
randomized to receive IFN-γ, GM-CSF or placebo for 3 alternate day doses, 
followed by a second LPS dose on day 7. The placebo group had an initial 
increase in the cytokine levels of TNF-α, IL-6, IL-10 and IL-1RA after the first 
LPS dose, but after the second dose a reduction in TNF-α production was 




second LPS dose, there was a trend of lower IL-10 but this did not reach 
statistical significance. HLA-DR expression decreased following the first dose 
of LPS, but appeared to recover prior to a subsequent similar depression in 
response to the second LPS dose. Compared to placebo, IFN-γ increased 
TNF-α and HLA-DR, with decreased IL-10, and was more effective than GM-
CSF in achieving monocyte activation.   
Spies et al, PLoS One, 2015 (Major Elective Surgery) 94 
This recent randomized controlled trial examined the role of continuous 
intravenous infusion of GM-CSF in elective esophageal and pancreatic 
resections in preventing post-operative infection. Crucially, only patients with 
empirically proven low monocyte HLA-DR expression measured on post-
operative day 1 were eligible. While we have discussed using a single 
observation to trigger immunoadjuvant therapy, more than one subnormal 
value could ascertain the deficiency more clearly. Sixty-one patients in total 
were included, equally distributed into a GM-CSF group, influenza vaccination 
and placebo. As expected, the GM-CSF treated group developed significantly 
higher monocyte HLA-DR expression compared with placebo. However, daily 
HLA-DR measurements were used to assess the response and as soon as 
the treated patients reached the threshold of 10,000 monoclonal antibodies 
(mAb) per cell, therapy was stopped. Therefore, duration of this 
immunoadjuvant was short, lasting between 1-3 days of continuous 
intravenous infusion. The result of this was a rapid return of monocyte HLA-
DR to the depressed levels of the other two groups by post-operative day 5. 
Note the similarity of this “post-treatment dip” to our group’s prior interferon-




number of “infection days” in the GM-CSF treated patients, but the post-
operative infection rate was similar between groups. The learning point may 
be that single monocyte HLA-DR measurement of response may not be an 
optimum marker of treatment effect. In addition, the immunological benefits 
from GM-CSF appear transient (at least in circulating monocytes) and 
therefore therapy probably should continue to at least 7-14 days based on 
several other studies when the peak of post-operative infection rates might 
occur.    
 The decision to include an arm of influenza vaccine and its apparent 
association with increased delirium detracts from the clarity of this work.  
 
G-CSF 
Schneider et al, Ann. Surg, 2004 (Major Elective Surgery) 95 
Prophylaxis with granulocyte colony stimulating factor (G-CSF) was 
given pre-operatively in patients undergoing major extirpative surgery. Sixty 
patients were divided equally into three arms; two different G-CSF regimens 
and placebo. In the first regimen, subcutaneous G-CSF was given on 
perioperative days -2, 1 and 3, compared with the second regimen with a 
dose on day -2, with smaller subsequent doses on the following 5 days. 
Operations included colectomy, gastrectomy, Whipple 
pancreatoduodenectomy, esophagectomy, and liver and lung resection. 
Patients who received G-CSF had increased TNF-α production, HLA-DR 




decreased rates and severity of infection in the treatment group. Interestingly, 
the authors stated that, in their opinion, monocyte deactivation was 
irreversible, and that this therapy exerted its effects by increasing the 
functioning number of leukocytes.  While this study included an odd collection  
of extensive operations, the differences described are worthy of future work. 
 
Bo et al, L. Crit Care 2011 (Sepsis)  96 
In 2001, Bo et al undertook a meta-analysis of 12 RCTs using either G-
CSF or GM-CSF in sepsis. This included a total of 2380 patients. The vast 
majority of studies included did not target therapy specifically for those with 
impaired monocyte function.  While this study demonstrated a trend of lower 
deaths in the treatment groups, there were no statistically significant 
differences in 28-day mortality for either immunoadjuvant. That being said, in 
three trials of G-CSF and one trial of GM-CSF, both agents appeared to 
significantly reverse infection.  
Alternative approaches  
While beyond the scope of this chapter, there have been various 
alternative approaches for immunomodulation even including extra-corporeal 
blood and plasma filtration. Early work has shown that endotoxin filtration 
combined with immune stimulation improves survival in a murine model of 
sepsis 97. Endotoxin filtration, such as with polymyxin B cartridges, have been 
accepted therapy in Japan in severe sepsis with approval also for many years 




(such as CYTOSORB®) have the potential for filtering “harmful” pro-
inflammatory cytokines. This principle is probably oversimplified, and 
elucidating optimum timing, if any, will be very difficult. Nevertheless, there is 
not yet acceptable evidence at present for its use in USA.  
 
c. Challenges of therapy  
Providing the patient with a reliable immunoadjuvant to treat the underlying 
pathophysiology of a major insult, whether it specifically addresses monocyte 
impairment or other aspects of the response, remains an old conundrum yet 
to be resolved.  
Spontaneous insults such as major trauma, burns or sepsis are a 
difficult issue to control for in a prospective, randomized fashion. With such 
heterogeneity, ensuring equal distribution between treatment and placebo 
groups is difficult, as discussed. Furthermore, each patient will have 
numerous treatments ranging from antibiotics, fluid therapy, inotropic support 
and potentially mechanical ventilation, not to mention source control. With so 
many variables, proving that the addition of a single adjuvant can make a 
statistically significant improvement in mortality becomes difficult.  
Many studies may initially show improvement with short term 
outcomes, yet when one examines 90 day mortality it often remains 
unchanged 99. Timing is a major issue not just for follow up, but also with the 
introduction, duration and cessation of therapy given the changing immune 




The immune system is redundant, which is likely a product of evolution. 
With so many different positive and negative effects of various inflammatory 
pathways, changing or altering one protein is not likely to ultimately change 
the outcome for a given patient. Indeed, it may have unrecognized negative 
consequences, such as those seen in early corticosteroid and anti-TNF-α 
therapeutic trials. Compare this, however, with the common use of brief 
perioperative antibiotic prophylaxis for clean-contaminated elective 
operations. Antibiotics were in use by surgeons for more than 20 years before 
definitive clinical proof was accomplished; this is now the most common use 
of antibiotic agents in the world. In retrospect the persuasive experiment was 
the pre-operative antibiotic dose 100.  
Although not specifically aimed at monocyte function, a meta-analysis 
of the effects of immune adjuvants in the context of sepsis is shown in Figure 
10 101. 
Early approaches, specifically for sepsis, targeted the apparent 
exuberant pro-inflammatory response, the so called “cytokine storm.” The 
rational for a therapeutic target was the predominance of TNF-α, IL-6 and IL-
1β production from innate immune cells such as monocytes, leading to 
endothelial activation and the release of acute phase proteins contributing to 
vasodilation, shock, acute respiratory distress syndrome and multi-organ 
failure. Furthermore, blockage or binding of LPS may be able to lower the 
PAMP load to limit the foregoing cascade. A simple “dampening” of the 
immune system with corticosteroid therapy has remained controversial. 
Moreover, this approach has never convincingly improved mortality. The only 




activated protein C. Despite the initial success of the PROWESS trial, 
concerns for its efficacy and bleeding side effects lead to the subsequent 
PROWESS-SHOCK trial in 2012. Those investigators concluded that 28 and 
90 day mortality were not significantly different, leading to subsequent 










Therapeutic efficacy of mediator-targeted therapy for sepsis. This meta-
analysis demonstrates relative risks and confidence intervals of various 
immune modulators are plotted based on the probability of death compared to 
the untreated controls. A relative risk of 1 indicates no difference in survival, 
and a relative risk of less than 1 indicates that the therapy has a decreased 
probability of death, thus is superior to untreated controls. Unfortunately, 
when many of these therapies were expanded to larger studies or different 
populations, the potential to improve mortality was not fulfilled.  




Eritoran is a synthetic lipid A antagonist to MD-2-TLR4 that was 
recently used in a randomized controlled trial of 1961 patients diagnosed with 
severe sepsis. This followed previous strategies targeting endotoxemia (such 
as lipid A antibodies). In this large phase III trial, the placebo group had a 
mortality of 27%, much lower than the 40% anticipated by investigators. 
Furthermore, patients with gram positive infection actually appeared to do 
worse than placebo. In contrast to a smaller phase II trial preceding it, there 
was no decrease in 28-day or 1 year mortality 102. 
 
d. The future of monocyte biology in the surgical patient  
Since the continued failure of clinical trials to show a mortality benefit 
between major trauma and sepsis, consensus in the literature seems to be 
moving towards ever more targeted therapy 20,21,49,103. For example, treating 
only those patients with depressed monocyte HLA-DR with IFN-γ, rather than 
non-specifically treating all patients. Such a strategy surely reduces the 
denominator, thus enhancing the demonstrable positive effects of putative 
treatments.  
This approach, therefore, needs a biomarker that would accurately 
represent the underlying immune phenotype, be present early enough to allow 
the benefit of therapy, and also respond to therapy in order to guide treatment 
response.  
In many diseases, miRNAs have been found to be stable and reliable 




have identified miRNAs that are dysregulated in patients with sepsis 104-107. 
More recent studies have implicated miRNAs in the host defense to trauma 
108-110. In general, these studies have not been correlated to underlying 
monocyte phenotype. It remains unclear if these markers could fulfill some of 
our criteria. For example some miRNAs such as miRNA-133a have been 
linked to increased mortality in sepsis 111. In-vitro studies using cell lines have 
shown that manipulation of such miRNAs could abrogate monocyte 
impairment; but as it stands there appears to be no immediate miRNA-based 
immunotherapy planned for human trials.  
It has been postulated that negative co-stimulatory markers such as 
PD-L1 are increased in patients with sepsis. There are few trials 
demonstrating this phenotype in major elective surgery or trauma. However, 
the apparent success with anti-PD-1 & anti-PD-L1 based therapy for 
malignant melanoma in humans may indicate that such therapy could be 
utilized for trauma or septic patients exhibiting this immune phenotype.  
e. Future immunoadjuvants  
It is not just PD-1 based therapies that are targeting T-cell defects in 
sepsis patients. Recent murine studies of sepsis models promise that IL-7 and 
IL-15 monoclonal antibodies increase the activity and function of T-cells. This 
may in turn increase endogenous IFN-γ and restore the healthy monocyte-T-
cell interaction. However, much more research is required before this can 
reach human clinical trials. The current list of registered trials for trauma and 





Table 4. Current trials relating to monocyte function (clinicaltrials.gov). 
 
Trial number Centre Type Setting Intervention Status 
NCT01649921 Radbound, 
Netherlands 
Interventional Sepsis IFN-γ Recruiting 
NCT02361528 Lyon, France Interventional Sepsis (& low 
HLA-DR) 
GM-CSF Not yet 
open 
NCT01653665 Newcastle, UK Interventional Sepsis (& 
PMN <50%) 
GM-CSF Completed 








Sepsis N/A Completed 
NCT02246595 Jena, Germany Interventional Septic shock CaCP29 Recruiting 
NCT01378169 Paris, France Observational 
(Monocyte 
microRNA) 
Sepsis N/A Unknown 
NCT02576459 Bristol-Myers 
Squibb, Site not 
specified, USA 
Interventional Septic shock Anti-PD-L1 Not yet 
open 
NCT02186522 Edinburgh, UK Observational Sepsis N/A Not yet 
open 
 






The predisposition and response of the immune system as a factor in the 
outcome of the surgical patient remains as relevant in 2016 as it ever has. As 
high-throughput systems approaches to trauma and sepsis, such as the  
Inflammation and the Host Response to Injury Project, continues we 
recognize an increased level of complexity with more and more molecules 
associated with poor outcomes such as nosocomial infection and indeed 
death. The field has progressed well beyond a rudimentary pro- or anti-
inflammatory response to a given insult. Yet the same challenges remain. 
With this increased knowledge, how can the physician hijack the immune 
system to improve the outcome of a patient? The question of what therapy 
might be optimum, and the timing and duration of this, remains.  
 In a previous chapter, it was discussed how there may be different 
components to a patient who has impaired host defenses, and indeed one 
biomarker, or therapy may not fit all. For example, perhaps interferon-gamma 
or GM-CSF is the right adjuvant for the patient with proven impaired monocyte 
function, and anti-PD-1 therapy might be appropriate for the patient with 
proven T-cell anergy with elevated PD-1 expression. In this chapter, one of 
the most promising agents is still interferon-gamma, but the persuasive trial 
that is adequately powered and targeted to those with impaired monocyte 
function has not been done. Much of the failed translation of pre-clinical 
studies to human trials for certain therapies may be in part due to the limits of 
murine research, the complex genetic and post-translational variation in our 
patients, and an incomplete understanding of how our very redundant immune 




 At present, there is insufficient evidence for the use of interferon-
gamma, G-CSF or GM-CSF in the adjuvant setting for major trauma, surgery 
or overt infection. Furthermore, new therapies, with apparent success in the 
oncologic setting, have yet to be trialed. Currently registered trials discussed 
here will hopefully answer some of these questions. We believe that while 
mortality has yet to be convincingly reduced with the use of such agents, the 
approach of targeting patients with proven monocyte impairment for the right 
duration, whatever that might be, holds potential in improving outcomes in 
some of our patients.  
In summary, this chapter has shown that corrective therapy to restore 
monocyte function in surgical patients has gained considerable traction for 30 
years, but no convincing improvements in mortality rates have been 
demonstrated. Furthermore, these clinical considerations highlight the 
incomplete understanding of how the immune response can become 
“maladaptive”. In order to achieve the ultimate goal of reliably identifying 
patients with impaired monocyte function and to correct this defect to improve 
outcomes, there is a need for better understanding the mechanisms by which 
the impairment takes place. Therefore, the work in this dissertation focuses on 
understanding how an insult such as endotoxin exposure might change 
intracellular signaling and lead to a suppression of the human monocyte 
inflammatory response.  
 
 





HYPOTHESIS, SPECIFIC AIMS AND EXPERIMENTAL PLAN 
 
A. Key Objective 
To develop a clinically relevant in-vitro model of monocyte impairment and 
study the defects in underlying signaling that lead to the suppression of pro-
inflammatory cytokine production which may predispose critically-ill surgical 
patients to nosocomial infection and death.  
B. Hypothesis 
LPS induced monocyte impairment occurs through sustained feedback 
inhibition of IκK, leading to decreased TNF-α production, also represented by 
decreased HLA-DR expression & increased IL-10 production. 
This dissertation focuses on TNF-α as a valid marker of monocyte function.  
C. Specific aims 
1. Develop a model of monocyte impairment, in which low dose 
endotoxin exposure leads to altered cytokine responses, analogous to that 
seen in some trauma and complex surgical patients. 
2. Investigate whether decreases in the cytokine response of the 
impaired monocyte is due to inhibition of IκK, leading to subsequent 




3. Determine which cytokines other than TNF-α and IL-10 are impaired, 
and determine the influence of IκK on their production.  
D. Experimental Plan 
The purpose of this project was to develop a model of monocyte impairment 
using isolated human monocytes. We anticipated that the in-vitro model would 
allow monocytes to have suppressed cytokine responses, specifically 
decreased TNF-α production, and decreased HLA-DR expression, 
recapitulating the defect seen in the critically-ill surgical patient.  
We then examined the underlying signaling mechanisms, starting with 
differences in TNF-α gene expression (mRNA) between naïve monocytes and 
those which are impaired. We then worked proximally in the signaling 
pathway to examine the differences in NFκB function and then IκK function. 
We anticipated decreased activation of both complexes of this important 
pathway in the impaired monocyte. This was indeed the case, therefore we 
then examined upstream circuitry of IκK to investigate dysregulation in toll-like 
receptor (TLR) signaling as well as miRNA’s which regulate this complex 
network. Finally, we took a global view of a wide variety of cytokine and 
chemokine levels to determine which other functions are suppressed as part 





















 i. Monocyte isolation 
Approval was given by the University of Louisville Institutional Review Board 
(IRB) (“Study of Immunological and Genetic Markers in Hospitalized and 
Ambulatory Subjects”, 0.0018) and written informed consent was obtained 
from all donors. The age of donors ranged from 18 – 54 years. A pool of 18 
donors (10 male) in total were used for donation, although between 4 and 10 
donors were used for a given experiment. Exclusion criteria included acute 
illness, anti-inflammatory medications, diabetes mellitus and any 
immunosuppressive conditions. 
 Up to 25 mL of venous blood was collected in EDTA Vacuntainer 
tubes (Becton Dickinson, Frankin Lakes, NJ). The collected blood was then 
incubated with CD14 magnetic microbeads and primary human monocytes 
isolated using a positive selection magnetic cell sorting technique according to 
manufacturer’s instructions (Miltenyi Biotec, Auburn, CA). In brief, after 15 min 
incubation with the microbeads, cells were washed with MACS Separation 
Buffer, resuspended and run through magnetic columns. Columns were then 
washed three times to eliminate non-monocyte material, before cells were 
eluted with MACS Elution Buffer. Cells were then counted to check for total 
number, purity and viability of the isolate using Trypan Blue staining.  
 Primary monocytes were then cultured in 1640 RPMI medium (MP 
Biomedical, Solon, OH) with 10% heat-inactivated Fetal Bovine Serum, 2 nM 




anti-mycotic (250 ng/mL amphotericin B). All the above were purchased from 
Thermo Scientific, Waltham, MA. Monocytes were cultured at 37°C in a 
humidified incubator at 5% carbon dioxide concentration. Cells were cultured 
either at 0.25 x 106 cells/mL after initial isolation or 0.5 x 106 cells/mL after 
resuspension at 17 hrs depending on the experimental conditions. Fifty mL 
polypropylene tubes were used for these single cell suspension experiments 
(VWR, Westchester, PA).  
 Lipopolysaccharide (LPS) from E.Coli 0111:B4 was used for cell 
stimulation, at doses of either 10 ng/mL or 100 ng/mL depending on 
experimental conditions which were based on preliminary experiments 
(Sigma-Aldrich, St. Louis, MO).  
 
ii. In-vitro induced monocyte impairment 
To develop impaired monocytes, the following steps were undertaken; 
cultured cells from a given donor were divided into separate tubes and rested 
for 1 h. At 1 h, “naïve” monocytes were cultured in media only, however 
“impaired” cells were given low dose LPS (10 ng/mL) at this time. Cells were 
then cultured in parallel for a further 16 h. At the 17 h time point, cells were 
centrifuged at 1800 rpm, counted and resuspended in fresh media. This step 
ensured that each condition had equal concentrations of viable monocytes for 
comparison. Cells at all conditions were then given a high dose, LPS 




iii. Cytokine assays 
Two series of cytokine assays were used to determine cytokine supernatant 
protein concentrations. Following cell culture incubations, tubes were 
centrifuged at 2000 rpm for 10 mins to ensure an acellular supernatant. This 
supernatant was then aspirated and stored at -80°C until subsequent 
analysis. For individual key cytokines, TNF-α, IL-10 and IL-6 concentrations 
were quantified by enzyme-linked immunosorbent assay (ELISA) kits 
(eBiosciences, San Diego, CA). ELISA assays were run in 96 well plates in 
accordance with manufacturer’s instructions. A standard curve was generated 
using recombinant TNF-α, IL-10 or IL-6 as appropriate. Activity was measured 
using a SpectraMax Plus384 spectrophotometer at a 450 nm wavelength. All 
samples were measured in duplicate. 
  For multiplex cytokine experiments, 25 µL of supernatant sample 
were used per well in duplicate in pre-mixed 96 well plates using magnetic 
beads for 29 different cytokines and chemokines as per manufacturers 
recommendations (Milliplex Human Cytokine/Chemokine 29-Plex Magnetic 
Bead  kit, EMD Millipore, Billerica, MA). Recombinant pre-mixed beads were 
used to create a standard curve. Quality controls 1 & 2 were used. Plates 
were run using a Luminex MAGPIX instrument (EMD Millipore, MA).   
  iv. Flow cytometry 
Monocyte cell culture samples containing 100,000 cells were washed twice in 
Phosphate Buffered Saline (PBS) by centrifugation and resuspended in 100 µl 
of PBS. Cells were stained with fluorescein isothiocyanate (FITC)-labeled 




(BD Biosciences, La Jolla, CA).  Cells were stained for 25 minutes, before two 
further PBS washes and fixation in 300 µL of 1% paraformaldehyde solution 
until subsequent analysis. Flow cytometric analysis was undertaken using a 
FACS Calibur flow cytometer (Becton Dickinson, San Diego, CA). A minimum 
of 3,000 gated events were acquired for each sample. Cell Quest software 
was used to determine cell purity (based on CD14 and HLA-DR positivity) and 
mean fluorescence intensity (MFI).  
For phosflow analyses for determination of pathway activation by intracellular 
protein phosphorylation, 100,000 cells were fixed with 3.2% formalehyde and 
washed twice after culture with stain buffer (PBS containing fetal bovine 
serum 2%) and permeabilized with 100% methanol for 30 min at -20C. Cells 
were then resuspended in 100 µL stain buffer and incubated for 1 h in the 
dark with either phospho-p65 or phospho-p38 MAPK (BD Biosciences, La 
Jolla, CA). Finally, cells were then washed twice with stain buffer and run 
fresh within 2 h  of stimulation using the FACS Calibur as described above.    
v. RNA isolation 
  In order to obtain RNA, after a given time point of cell culture, cells 
were pelleted and stored in 300 µL of lysis buffer at -80°C. RNA was extracted 
using the MirVana RNA extraction kit (Thermo Fisher Scientific, Waltham, 
MA).  
 For quality control testing, RNA purity and concentration was 
measured using the Nanodrop N-1000 (Agilent Biosystems, Santa Clara, CA). 
Samples were only used if they fulfilled the quality control criteria of 1.8 – 2.2 




ratio). This excluded samples of poor, unreliable quality that were at risk of 
containing contaminating DNA, protein or other organic compounds.  
vi. mRNA measurements 
To determine the expression of individual genes of interest, RNA was diluted 
to 2 ng/µL concentration and used to synthesize complimentary DNA (cDNA) 
by reverse transcription (High Capacity cDNA Reverse Transcription kit, Life 
Technologies, Foster City, CA).  
Quantitative real time polymerase chain reaction (qRT-PCR) was undertaken 
with Taqman® 20X specific mRNA primers, such as those for TNF-α, using 
18S as an internal control. Samples were run in duplicate in a 96 well plate 
using Taqman® Universal Mastermix (all of the above from Life Technologies, 
Foster City, CA).  
For data analysis, a ΔRn (normalized reporter value i.e. signal) threshold of 
0.1 was chosen based on the linear part of the gene expression curve. Fold 
changes were calculated using the ΔΔCT method 112.  
 For TLR signaling, pre-coated mRNA profiler plates were used (Taqman® 
Array Human Toll Pathway, Core Components, Life Technologies, Foster 
City, CA). Each of the 48 wells received 3 ng of cDNA (44 wells with gene of 
interest, 4 of internal controls). Taqman® Universal Mastermix was used to 
make a reaction volume of 10 µL per well. For these experiments, a 
combination of 18S, GAPDH, and Beta2-Microglobulin were used for internal 
controls. The StepOne Plus RealTime-PCR-System instrument was used for 





For microRNA screening, Taqman® Microfluidic Low Density Array Cards 
were used with a total of 1500 ng of diluted RNA per card, divided between 
384 wells (Card A, Life Technologies, Foster City, CA).  Once samples were 
loaded (100 µL per port), cards were sealed and centrifuged at 2000 rpm for 2 
mins. They were then run using a ViiA™ 7 Real-Time PCR System (Applied 
Biosystems®, Foster City, CA). Four separate wells with RNU6, along with 
RNU44 and RNU48 were used in combination for an internal control. 
For single assay microRNA quantification, specific 5X primers were used per 
microRNA for reverse transcription to create cDNA, with specific 20X primers 
used for qRT-PCR with Taqman® Universal Mastermix using a reaction 
volume of 10 µL. The internal control used was RNU6, and all assays were 
run in duplicate using a 96 well plate using a StepOne Plus RealTime-PCR-
System instrument (Applied Biosystems®, Foster City, CA). Like messenger 
RNA analysis previously described, all microRNA data was analyzed using a 
cycle threshold of 0.1 using the ΔΔCT method 112. 
viii. Western Blot analysis 
For intracellular protein quantification, monocyte cell culture tubes were 
centrifuged for a given time point, the cell pellet lysed using RIPA buffer with a 
1:1000 concentration of protease and phosphatase inhibitors (Thermo 
Scientific, Rockford, IL) and stored at -80°C until subsequent analysis. For 
protein extraction, lysed cells were then sonicated using a Sonifier 250 
(Branson Ultrasonics, Danbury, CT). Protein concentrations were quantified 




Scientific, Rockford, IL) against a standard curve using a SpectraMax Plus384 
spectrophotometer at 540 nm.   
Protein samples of 30 µg were loaded into gradient 4-12% Bis-Tris Plus 12 
well gels in combination with 4X BoltTM LDS Running Buffer with 1:100 2-
mercaptoethanol. Gels were run in a BoltTM Mini Gel Tank in Bolt MES SDS 
Running Buffer at 180 mV for 45 min (all from Thermo Scientific, Waltham, 
MA). Each gel contained two wells loaded with a protein size standard to 
identify the size of proteins of interest (Protein Western C Standard, Bio Rad, 
Hercules, CA).  
After gel electrophoresis, proteins were transferred to a nitrocellulose 
membrane using iBlot Gel Transfer Stacks and an iBlot transfer device (Fisher 
Scientific, Hampton, NH).  
Membranes were then blocked with 5% non-fat dried milk in TBS-T (Tris base 
9.68g, sodium chloride 32g and Tween-20 100 µL in 100 mL deionized water 
adjusted to pH 7.6) for 1 h at room temperature to prevent non-specific 
binding. Membranes were then incubated overnight with primary antibodies 
(either rabbit or mouse anti-human) at room temperature. All antibodies were 
purchased from Cell Signaling (Danvers, MA). Antibody concentrations were 
as follows; Beta-actin 1:10,000, Vinculin 1:1000, NFκB p65 1:1000, IκB 
1:1000, IκK-α 1:1000, IκK-β 1:1000, TAK-1 1:1000 diluted in 5% non-fat dried 
milk with TBS-T. Phospho-IκK and phospho-TAK1 were diluted at 1:1000 in 
5% Bovine Serum Albumin (BSA)  in TBS-T (non-fat dried milk was not used 
with phosphorylated antibodies to prevent casein interfering with sites of 




washed three times for 5 min in TBS-T before incubation with secondary 
antibodies (goat anti-rabbit or horse anti-mouse as appropriate) at a 
concentration of 1:1000 for 1 h at room temperature. 
After a further three washes as above, membranes were finally incubated in 
Pierce ECL Substrate for 5 min (Thermo Scientific, Waltham, MA). Finally, the 
membrane was imaged using the ChemiDoc MP system (Bio Rad, Hercules, 
CA, courtesy of Dr. Jason Smith) and protein densitometries measured using 
ImageLab software (Bio Rad, Hercules, CA). For each protein of interest, 
relative density units were expressed as a ratio over an internal loading 
control from the same sample (either Beta Actin or Vinculin depending on the 
molecular weight of the protein).  
ix. Inhibition of IκK  
 To determine the direct role of IκK in monocyte function and dysfunction, a 
small molecule specific inhibitor of IκK called IκK-16 was purchased (Sigma-
Aldrich, St. Louis, MO). It was prepared in accordance with manufacturer’s 
instructions. In brief, powder preparation was reconstituted in 180 µL of 
dimethyl sulfoxide (DMSO) and aliquoted in stock 10 µL ampules and stored 
at -80°C. For each experiment, IκK-16 was prepared fresh by a 1:50 dilution 
with DMSO from stock and then diluted in 1:1000 with media (as described 
under Monocyte Isolation) for use.  Doses of IκK-16 were given at 100 nM 
unless otherwise specified. For a 100 nM dose, 100 µL of IκK-16 was given 
per mL of cultured cells. Preliminary experiments demonstrated that DMSO 




Loss of function of IκK phosphorylation is confirmed in the Results section of 
Specific Aim 2 (see Figure 29).  
 
 
x. Statistical analysis  
Data are shown as mean ± standard error of the mean. For a given condition, 
each donor was compared within the same individual. Therefore, in general 
paired, related analyses were used. For individual comparisons, a two-tailed 
paired t-test or Wilcoxon signed rank were used. Statistical analyses were 
performed using SPSS version 21 (PASW Statistics, IBM, Chicago, IL). 
Significance was determined with an alpha of 0.05. Sample size calculations, 
power analyses and more complex statistical analyses are described in the 






DEVELOPING A MODEL OF MONOCYTE IMPAIRMENT 
INTRODUCTION 
 
Monocyte impairment is estimated to occur in approximately 1 in 6 patients. It 
is not clear whether these patients have a genetic predisposition limiting their 
cellular responsiveness, or whether this is acquired from the insult itself. 
Therefore, predicting which patients will have monocyte impairment is 
challenging. The study of mechanisms and modulation of monocyte 
impairment in surgical patients is complex and expensive. There are a large 
number of additional factors which may influence these measurements such 
as co-morbidity and the effect of interventions such as surgery, antimicrobial 
drugs and adjunctive drugs such as heparin and fluid therapy. Therefore, 
study of the human immunological response to a major insult in a consistent, 
reproducible way requires an alternative solution.  
 Sepsis models in animals, such as mice, have been used to study 
monocyte impairment in a variety of approaches. This often involves 
intraperitoneal delivery of endotoxin, before either a further in-vivo challenge 
or isolation of peritoneal macrophage or bone marrow derived cells for ex-vivo 
LPS stimulation. The major limitation with this approach is whether the 
findings can be extended to a human population. This was eloquently 




2013 113. Cell lines have the benefit of being of human origin and are 
reproducible, however, do not offer the genetic variability that exists in the 
human population.  
 In this model, we use monocytes from healthy volunteers to preserve 
the variability from person to person, that are impaired equally in standardized 
fashion by an initial low dose of LPS (10ng/mL). The goal was to produce a 
model where the cells with previous exposure to LPS have a reproducible d 
ecrease in their capacity to produce TNF-α in response to a subsequent 
challenge. TNF-α is the most defined and accepted marker that defines a 
blunted monocyte response in high quality immunological studies. However, 
IL-10 and HLA-DR expression represent important functions of the monocyte 
which also bear clinical correlation and therefore were also measured.  
RESULTS 
Isolated Monocyte Culture – Cell Purity and Viability 
Prior to isolation, leukocytes in whole blood can be seen in three broad 
categories by flow cytometry which are neutrophils (polymorphonuclear cells), 
lymphocytes and monocytes (circled, Figure 12A). Following CD14 magnetic 
bead isolation, a single cell population can be observed (Figure 12B). A small 
amount of debris can be seen in the bottom left hand corner of this scatterplot, 
which is normal for cells after culture and multiple centrifugations. By gating 
on the monocyte population (as per the circle in Figure 12B), consistently 
over 95% these cells are highly positive for the monocyte markers CD14 
(FITC) and HLA-DR (PE). A representative scatterplot is shown in Figure 




Figure 12. Monocyte purity following CD14 magnetic positive selection 
technique from whole blood.  
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Legend for Figure 12.  
 
The distribution of monocytes in a three-part differential of leukocytes in whole 
blood prior to monocyte isolation is shown in (A), based on its size (forward 
scatter, FSC) and granularity (side scatter, SSC) properties. Following 
isolation by magnetic bead positive selection technique, a single cell 
population is identified in the gate circled (B). Material in the lower left hand 
corner represents debris, normal for flow cytometry of such cells. Of the cells 
isolated, 99.3% of gated cells are CD14 (FL1) and HLA-DR (FL2) positive 
demonstrating a pure, viable monocyte population (C). This representative 
















The viability of isolated monocytes were determined by culturing cells over 
time and number of viable monocytes manually counted by standard 
microscopy after Trypan blue staining. By 24 hours, cell loss is approximately 































Hours after Monocyte Isolation 








After isolation of monocytes from healthy volunteers, cells are cultured and 
divided into two conditions; naïve and impaired. After 1 h of rest, the naïve 
cells remain in media only until 17 h. By comparison, low dose 10 ng/mL is 
added to the impaired cell culture until 17 h.  At 17 h, tubes of cell suspension 
are centrifuged, and cells are washed and counted by microscopy and 
resuspended to 0.5 x 10 6/mL concentration to ensure equal cell 
concentrations across both naïve and impaired conditions. Cells are then 
challenged with 100 ng/mL LPS to determine monocyte responsiveness at 





The viability of these cells in culture were studied over time, demonstrated in 
Figure 13. It should be noted that there is a relatively consistent loss of 
monocytes of approximately a third by 24 hours, reaching approximately a 
half of cells by 48 hours after cell isolation.  
 Experimental design of the impaired monocyte model is described in 
detail in the Methods section, but is summarized in Figure 14. 
TNF-α production 
The naïve cells in standard media without initial low dose LPS stimulation 
secreted approximately 1500 pg/mL TNF-α by 17 hours (Figure 15). Low 
dose LPS 10 ng/mL stimulated a trend towards increased TNF-α levels by 17 
hours. After cells were washed and resuspended, both conditions were 
cultured with a 100 ng/mL LPS challenge. In general, the TNF-α levels in both 
conditions were lower at time points after 17 hours compared with those at the 
end of the initial 17 hour interval. Critically, the naïve cells (illustrated in green) 
were able to produce a consistently higher level of TNF-α after the 100 ng/mL 
LPS challenge, compared to the impaired cells which demonstrated sustained 
suppression of TNF-α production in response to such an 100 ng/mL LPS 
challenge (seen maximally at 4 and 12 hours after the 100 ng/mL LPS 
challenge).  
IL-10 production  
In contrast to TNF-α, IL-10 levels in general increased over time in culture for 
both conditions (Figure 16). In response to the initial 10 ng/mL LPS, IL-10 




hours, without reaching statistical significance. However, in response to the 
100 ng/mL LPS challenge, the capacity for monocytes to produce IL-10 was 
consistently suppressed in the impaired cells at 4, 12 and 24 hours after the 
100 ng/mL LPS challenge.  
HLA-DR expression 
In both conditions, HLA-DR expression increased over the first 17 hours from 
baseline levels after isolation. Low dose 10 ng/mL LPS caused a small but 
consistent decrease in HLA-DR expression compared to the naïve cells 
(Figure 17). This equated to impaired cells expressing approximately only 5-
15% lower levels of HLA-DR compared to the naïve cells; however there was 
a considerable amount of variability from donor to donor. There were no 






Figure 15. TNF-α production in the impaired monocyte.  
 
 
Supernatant protein concentration of TNF-α, a pro-inflammatory cytokine, was 
measured at various time points by ELISA to compare naïve cells (green) 
against impaired cells (red). Low dose LPS 10 ng/mL at 1 h leads to a modest 
increase in TNF-α production by 17 h in the impaired cells. However, in 
response to a high dose 100 ng/mL LPS challenge given at 17 h, the same 
impaired cells have a sustained suppression of TNF-α production thereafter 
when compared to the naïve cells. Mean ± SEM. N = 7. * p < 0.05, † p = 0.07. 
















































Figure 16. IL-10 production in the impaired monocyte.  











The supernatant protein concentration of IL-10, an anti-inflammatory cytokine, 
was measured at various time points by ELISA to compare naïve cells (green) 
against impaired cells (red). Low dose 10 ng/mL LPS at 1 h leads to a minor 
but not significant decrease in IL-10 concentration by 17 h in the impaired 
cells. However, in response to a high dose 100 ng/mL LPS challenge given at 
17 h, impaired cells have a sustained suppression of IL-10 production when 


















































There was a slight trend of low dose 10 ng/mL LPS increasing IL-6 production 
by 17 hours compared to naïve cells, but this did not reach statistical 
significance. Subsequent to the 100 ng/mL LPS challenge, the impaired cells 
had a sustained decrease in the ability to produce IL-6 when compared to the 
naïve cells (Figure 18). This was most evident at 29 hours and 41 hours 
(corresponding to 12 hours and 24 hours after the 100 ng/mL LPS challenge).  
TNF-α gene expression (messenger RNA) 
Figure 19 demonstrates differences in intracellular TNF-α messenger RNA 
levels relative to the naïve monocyte, as measured by qRT-PCR. Low dose 
10 ng/mL LPS in the impaired cells leads to a modest increase in TNF-α gene 
expression seen at 2, 4 and 8 hours after isolation. This difference begins to 
correspond to similar levels in the naïve monocyte by 17 hours. In response to 
the 100 ng/mL LPS challenge, however, TNF-α gene expression is decreased 
relative to the naïve monocyte. This difference is seen maximally at 19 hours 





















































































Legend for Figure 17.  
 
Monocyte HLA-DR, a MHC II class surface marker critical for the function of 
antigen presentation, was determined by flow cytometry at various time points 
(A). Mean Fluorescence Intensity of HLA-DR was measured comparing naïve 
cells (green) against impaired cells (red). Low dose 10 ng/mL LPS at 1 h led 
to a small but consistent decrease in HLA-DR expression at 17 h in the 
impaired cells. When both conditions were treated with a high dose 100 
ng/mL LPS challenge at 17 h, no significant differences in HLA-DR expression 
were observed between the naïve and impaired monocytes. Mean ± SEM. N 
= 7. * p < 0.05, Wilcoxon signed rank test. 
A histogram of HLA-DR expression in monocytes both naïve cells (white) and 
impaired cells (gray) at 17 h is shown in (B). This is a representative sample 










IL-6 supernatant protein concentration was measured at various time points 
by ELISA, comparing naïve cells (green) against impaired cells (red). Low 
dose 10 ng/mL LPS given at 1 h led to a minor but not significant increase in 
IL-6 production by 17 h in the impaired cells. However, in response to a high 
dose 100 ng/mL LPS challenge given at 17 h, impaired cells appear to have a 
sustained suppression of IL-6 production when compared to the naïve cells. 


































































































































TNF-α mRNA time course 
* 
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Legend to Figure 19.  
 
Intracellular TNF-α gene expression was examined in the naïve and impaired 
monocyte by qRT-PCR. A time course experiment is shown in the top graph 
using 4 donors (A). Low dose 10 ng/mL LPS upregulated TNF-α mRNA 
expression rapidly over the first 4 to 8 hours after treatment, then began 
“turning off” by 17 h. When both conditions were incubated with high dose 100 
ng/mL LPS challenge at 17 h, the impaired cells demonstrated a decreased 
level of mRNA expression relative to naïve cells. This genomic response early 
after LPS stimulation corresponds with the sustained differences seen in TNF-
α protein (shown earlier in Figure 15). The maximal level of suppression of 
TNF-α gene expression in the impaired monocyte is seen at 19 h, relative to 
the naïve monocyte (2 h after the 100 ng/mL LPS challenge). N = 4.   
The bottom figure represents qRT-PCR experiments focused at this 19 h time 
point (B). Impaired monocytes (red) have a profound downregulation of TNF-α 
mRNA relative to naïve cells. N = 8. Mean ± SEM. *p < 0.05, Wilcoxon signed 














 Monocytes have various critical immunological functions in orchestrating a 
well-balanced response to an insult. Cytokine production is a highly regulated 
set of small functional proteins allowing activation and differentiation of 
leukocytes governing the immune response. TNF-α and IL-6 represent pro-
inflammatory cytokines. These are produced early after a stimulus and 
activate the innate and adaptive system to in turn produce further cytokines, 
hence the term “cytokine cascade”.  This pattern is demonstrated by our data, 
where TNF-α and IL-6 are produced early and trend to an early increase in 
the 10 ng/mL LPS treated cells.  
 TNF-α is secreted primarily from monocytes and macrophages often 
within 30 min of an inciting event. As part of its autocrine function, it promotes 
the activation and differentiation of macrophages, prolongs their survival and 
increases their production from progenitor cells. Direct injection of TNF-α into 
animals produces a shock-like state, which is also associated with increased 
vascular permeability, pulmonary edema and activation of the coagulation 
system. TNF-α has been described as the “master regulator” of inflammatory 
cytokine production, but the blockade of TNF-α has been shown to improve 
mortality in animal models 114.  
 The suppression of TNF-α in response to a second LPS exposure has 
defined models of impaired monocyte function, or “endotoxin tolerance”, 
throughout immunology literature 5,68,69. In our results utilizing this type of 
model, there is a consistent depression of TNF-α production in cells with prior 




groups 7. Furthermore, the changes in TNF-α gene expression prove that the 
suppressed response occurs at a level of intra-cellular genomic signaling 
which is clearly different between the two conditions. These time course 
experiments demonstrate that increased TNF-α observed in response to 10 
ng/mL LPS is produced from newly synthesiszed messenger RNA, therefore 
true production in response to a stimulus, rather than pre-formed TNF-α 
released in impaired conditions compared with naïve monocyte. Contrast the 
changes in TNF-α gene expression seen in Figure 19A to the clinical 
scenario in Figure 1. We believe these similarities demonstrate the clinical 
relevance of our model.     
 IL-10 is a centrally important anti-inflammatory cytokine which has an 
important role in counterbalancing the pro-inflammatory response. In 
excessive amounts, IL-10 can lead to monocyte deactivation, with high levels 
related to the magnitude of injury. Our results show that IL-10 production, 
representative of the anti-inflammatory response, is also impaired in cells 
treated with prior 10 ng/mL LPS. This is in agreement with some groups 7,66, 
although various in-vivo studies demonstrate higher IL-10 levels 68,115. This 
difference may be related to the interaction between monocytes and T-cells 
which is not preserved in our model of single cell suspension.  
   Monocyte HLA-DR expression is reported less often in the literature 
than TNF-α in this type of experimental model. Our results show a decrease in 
HLA-DR expression in response to low dose 10 ng/mL LPS, however this 
difference is small and not seen at later time points by which both cellular 
conditions have received LPS exposure. The magnitude of the HLA-DR 




dose 10 ng/mL LPS in the context of cell activation by the process of isolation 
and ex-vivo cell culture, as demonstrated by the increased size and 
granularity properties of the monocytes compared to those seen in whole 
blood prior (pre-isolation) (Figure 12A & B), and the higher than expected 
levels of TNF-α in the naïve cells by 17 hours (Figure 15). This decrease in 
HLA-DR expression in the impaired cells is however consistent and broadly in 
keeping with literature findings 67,68.   
Elevated levels of IL-6 have long been associated with mortality in 
trauma and sepsis. IL-6 is a potent inducer of the acute phase response, with 
pleiotropic effects on proliferation, differentiation and maturation of progenitor 
cells as well as controlling cellular metabolic activities. These results 
demonstrate that impaired monocytes have a decreased capacity to produce 
IL-6 production in response to an LPS challenge. This is in keeping with 
previous literature 7,66,68.  
There were numerous difficulties in developing this model. Different 
rest periods after isolation were evaluated, including no rest, 1 hour and 8 
hours of rest. LPS doses of 2 ng/mL, 10 ng/mL and 100 ng/mL were tested as 
the initial stimulus. Both 16 and 24 hours were used for the initial duration of 
LPS exposure, and various monocyte cell concentrations were used. We 
found that after 1 hour of rest after isolation, followed by an initial dose of 10 
ng/mL LPS for 16 hours, led to the most consistent impairment of monocyte 
function in response to a subsequent 100 ng/mL LPS challenge (Figure 14).  
Therefore, the model appears to reproducibly produce monocytes 




production as well as decreased antigen-presenting capacity, as measured by 
HLA-DR expression. This model therefore allows for further study of the 
underlying immunological mechanisms of impaired monocyte function, an 





Figure 20. Calculating host defense liabilities as a causative factor in the 




There are multiple and often unpredictable factors relating to whether a 
surgical patient will be susceptible to nosocomial infection. This model of 
impaired monocyte function allows for the study of the ‘Innate and Adaptive 
Host Defenses’, and it’s ‘Acute Host Defense Liabilities’ in a reproducible 
fashion.  










Innate and Adaptive 
Host Defense 











IκK SIGNALING IN THE IMPAIRED MONOCYTE 
INTRODUCTION 
 
The knowledge and understanding of molecular mechanisms governing the 
immune response has improved considerably over the last 20 years. Various 
dynamic and complex inflammatory pathways, such as NFκB, respond to 
stimuli, but also have negative feedback regulation to counteract the pro-
inflammatory response. If these are inadequate, persistent inflammation can 
be harmful to the patient and can lead to multi-organ failure and death. By 
comparison, an exaggerated compensatory anti-inflammatory response can 
predominate which can lead to an impaired host response and insufficient 
pathogen clearance.  
 The previous chapter demonstrated a decrease in the monocyte gene 
expression of TNF-α in response to a subsequent LPS challenge. This 
suggests that there may be a difference in NFκB signaling between naïve and 
impaired conditions, as this is one of the critical mechanisms of pro-
inflammatory signaling. Activation of NFκB signaling occurs in response to 
TLR ligands like LPS, with a cascade of phosphorylation from its upstream 
kinase, Inhibitor of κB Kinase (IκK). Subsequently, the release of the “brakes” 
in the pathway, IκB, occurs which allows translocation of the active subunit 
p65 to the nucleus to activate pro-inflammatory genes such as TNF-α. 
Therefore, if this pathway is suppressed, this would account for the decreased 
monocyte responsiveness seen both in the impaired monocyte model and in 




downstream from NFκB and therefore when this pathway is activated, both 
the pro-inflammatory cytokines are synthesized but also the slower acting 
compensatory anti-inflammatory molecules are released.  
 The aim of this chapter is to first determine if there are alterations in 
NFκB signaling between the naïve and impaired conditions. If this was the 
case, we then could undertake a detailed study of IκK, upstream of NFκB, in 
terms of the total concentration and levels of activation in the impaired 
monocyte. This could then help elucidate the mechanisms underpinning a 
possible cause and effect relationship between IκK suppression and the 
diminished inflammatory response in the impaired monocyte.  
RESULTS 
NFκB signaling in the impaired monocyte 
Monocytes cultured in low dose 10 ng/mL LPS for 16 hours were challenged 
with an 100 ng/mL LPS challenge for 60 minutes. At this time point, impaired 
monocytes, which had demonstrated an impaired response in the previous 
chapter, had a lower protein concentration of p65, the active subunit of NFκB, 
compared to naïve cells (Figure 21 A & B). In addition, a representative 
histogram using phosflow technology demonstrated that these impaired cells 
have a decrease in the level of phosphorylation at 30 minutes after the 100 
ng/mL LPS challenge, compared to naïve monocytes (Figure 21C).  
Levels of IκB, the “brakes” in the NFκB pathway, were similar at 17 




by 60 minutes after the 100 ng/mL LPS challenge (Figure 22B), compared to 
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Legend to Figure 21.  
 
Monocytes were cultured either in naïve (media only) or impaired (low dose 
10 ng/mL LPS) conditions for 16 h. After resuspension in fresh media, cells in 
both conditions were cultured with the 100 ng/mL LPS challenge for 60 min. 
Cells were lysed and subsequently analyzed by Western Blot to determine the 
concentration of p65, the active subunit of NFκB, between conditions. Beta 
actin was used as a loading control. A representative blot is demonstrated 
showing decreased p65 concentration in the impaired monocyte (A). This 
reached statistical significance,* p < 0.05 (B). N = 6.  A representative 
phosflow histogram (C) demonstrates a higher peak of NFκB (p65) 
phosphorylation in naïve cells (green) compared to impaired cells (red) at 30 
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Figure 22. IκB signaling in the impaired monocyte.  
 










Isolated monocytes were rested for 1 h and then treated either with media 
only or low dose 10 ng/mL LPS for 16 h. Following washing and resuspending 
in fresh media, cells in each condition were challenged with 100 ng/mL LPS 
and NFκB was measured. Vinculin was used as a loading control. 
Representative Western Blots (A) demonstrate the effective degradation of 
IκB in naïve cells (green) by 60 min after the LPS challenge. By comparison, 
the impaired cells were less effective in IκB degradation by 60 min (B, * 
p<0.05, Wilcoxon Signed rank Test). N = 5. 
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Total levels of IκK-α & -β in the impaired monocyte  
Messenger RNA levels of the two critical catalytic subunits of IκK, -α and β, 
were measured by qRT-PCR at 17 hours to examine for differences in gene 
expression of IκK at the time of the LPS 100 ng/mL challenge (Figure 23). 
Impaired monocytes had decreased IκK-α messenger RNA relative to naïve 
monocyte.  There were no differences between IκK-β gene expression 
between naïve and impaired conditions.  
Despite the decrease in IκK-α mRNA, Western blot measurements did not 
show differences in total protein between naïve and impaired monocytes 
(Figure 24). In addition, there were no differences in IκK-β protein between 
naïve and impaired cells by Western Blot (Figure 24). 
Immunofluorescence was used by qualitatively examining the fluorescence of 
IκK-α and –β using Texas Red between naïve and impaired monocytes. 
There were no clear differences between naïve and impaired monocytes 
studied 30 minutes after the 100 ng/mL LPS challenge.  
IκK phosphorylation in the impaired monocyte 
Naïve and impaired monocytes were studied immediately before the 100 
ng/mL LPS challenge, and then every 15 minutes for 120 minutes to 
determine differences in IκK phosphorylation between conditions. In Figure 
26, IκK phosphorylation in the naïve monocyte occurred maximally at 30 and 
45 minutes, which then returned to unstimulated levels by 60 and 120 minutes 
following the 100 ng/mL LPS challenge. By comparison, IκK phosphorylation 
was decreased throughout the 120 minutes of study when compared against 




Figure 23. IκK-α & -β gene expression in the impaired monocyte.  
 
Monocytes cultured in either naïve (media only) or impaired (10 ng/mL LPS) 
conditions for 16 h following after an initial 1 h rest. At 17 h, which would 
represent the time of 100 ng/mL LPS challenge, monocyte RNA was analyzed 
for differences in the expression of IκK-α & IκK-β mRNA using qRT-PCR. 
Impaired monocyte IκK mRNA levels were expressed relative to naïve cells. 
These data show that IκK-α is downregulated in the impaired monocyte (p 
<0.05, Wilcoxon-signed rank test).  Gene expression of IκK-β did not differ 
between naïve and impaired conditions. N = 7.   
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Mins after 100ng/mL LPS: 
10ng/mL LPS pre-treatment: 
Figure 24. IκK-α protein in the impaired monocyte.  
 
  
IκK-α protein levels were measured in naïve and impaired monocytes by 
Western Blot, using beta-actin as an internal control. Monocytes were cultured 
in either media only (naïve) or 10 ng/mL LPS (impaired) for 16 hrs. After 
washing, cells were then treated with the 100 ng/mL LPS challenge. IκK-α 
was measured by SDS-PAGE (Western Blot) at the time of isolation, at the 
time of LPS challenge and 30 and 60 min after the LPS challenge (A). There 
were no significant differences between naïve and impaired conditions in 
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IκK-β protein levels were measured in naïve and impaired monocytes by 
Western Blot, using beta-actin as an internal control. Monocytes cultured with 
either media only (naïve) or 10 ng/mL LPS (impaired) for 16 hrs. After 
washing, cells were then treated with 100 ng/mL LPS challenge. IκK-β was 
measured by SDS-PAGE (Western Blot) at the time of isolation, at the time of 
LPS challenge and 30 and 60 min after the challenge (A). No significant 
differences between naïve and impaired conditions in terms of IκK-β protein 
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Monocytes were incubated in either naïve (media only) or impaired (10ng/mL 
LPS) conditions for 16 h before washed and resuspended. At this point, 100 
ng/mL LPS was given to both conditions and intracellular monocyte IκK 
phosphorylation was measured by Western Blot (A). Beta actin was used as a 
loading control for normalization. IκK phosphorylation was achieved in naïve 
monocytes maximally at 30 min after the LPS challenge. By comparison, this 
phosphorylation of IκK was not seen in cells pre-treated with 10 ng/mL LPS 
(impaired). N = 4.  Paired T-test.  
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TAK-1 signaling in the impaired monocyte 
Both phosphorylated and total levels of TAK-1 were measured over the same 
15 minute intervals after the 100 ng/mL LPS challenge. There were no 
consistent differences in the phosphorylated TAK-1 levels (expressed as a 
percentage of total TAK-1) or total TAK-1 levels between naïve and impaired 
monocytes (Figure 27).  
Toll-like receptor signaling in the impaired monocyte 
Naïve and impaired monocytes were profiled for dysregulated TLR signaling 2 
hours after the 100 ng/mL LPS challenge. Two of the 44 genes examined 
reached statistical significance and were both were downregulated in the 
impaired monocyte when compared to the naïve cell (Figure 28). These 
included TRAF-6, equating to approximately 5-fold downregulation, and 
NFκBIE by 1.6-fold downregulation in the impaired monocyte.  
Of interest, the gene for CD14 approached significance at p = 0.075, with 1.8-
fold downregulation. IκK-γ also decreased with a 1.5-fold downregulation (p = 
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Monocytes were incubated in either naïve (media only) or impaired (LPS 
10ng/mL) conditions for 16 h before 100 ng/mL LPS challenge. Intracellular 
monocyte TAK-1 (phosphorylation and total) was then measured by Western 
Blot every 15 min until 120 min (A). No differences between naïve and 
impaired monocytes were elucidated in levels of TAK-1 activation, expressed 
as a ratio of Phospho-TAK-1 over Total TAK-1 (after both were normalized 
with beta actin). N = 5. 
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Figure 28. Toll-like receptor signaling in the impaired monocyte.  
 
Monocytes were cultured in naïve (media only) or impaired (low dose 10 
ng/mL LPS) conditions for 16 h. After resuspension in fresh media, cells in 
each condition were stimulated for a further 2 hours with the 100 ng/mL LPS 
challenge. Intracellular RNA was assessed for gene expression of TLR 
signaling molecules (mRNA) using TLR profiling assays (qRT-PCR). 18S, 
GAPDH and beta-2-microglobin were used as internal controls. N = 4. Each 
dot represents a gene target. In this volcano plot, genes to the left of the 
vertical 0.66 line were considered downregulated (equivalent to a fold 
downregulation of 1.5) and those to the right of vertical 1.5 line were 
considered upregulated in the impaired monocyte relative to naïve conditions 
(control). On the y-axis, target genes above the horizontal line at 1.3 were 
considered significant (thus above line equivalent to p < 0.05, Paired T-test). 
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IκK-16 as an effective inhibitor of IκK phosphorylation 
Following pre-treatment with either 100 nM IκK-16 (diluted in DMSO) or the 
equivalent dilute DMSO control for 1 hour after isolation, monocytes were 
stimulated with 100 ng/mL LPS. Time points for measurement of IκK 
phosphorylation by Western Blot were taken at 1 hour (immediately before 
100 ng/mL LPS) and then at 15 minute intervals for 120 minutes. Figure 29 
demonstrates that control monocytes (with dilute DMSO only) responded to 
the 100 ng/mL LPS challenge with a peak of IκK phosphorylation after 15 
minutes. By comparison, levels of IκK phosphorylation were decreased in the 
IκK-16 treated cells even prior to the addition of 100 ng/mL LPS, and 
remained lower at 15 and 30 minutes after the 100 ng/mL LPS challenge as 
compared to the control.  
 Monocyte viability was measured at 17 hours following a range of IκK-16 
doses, ranging from a control without LPS, control (DMSO) with LPS, and 
then 1 up to 1000 nM concentrations of IκK-16. There were no differences in 
monocyte viability between conditions, with approximately 75% of cells viable 
at 17 hours (Figure 30).  
Effect of IκK-16 on cytokine production 
Under the same conditions, levels of TNF-α were measured by ELISA to 
determine if targeted IκK inhibition would decrease TNF-α production. Indeed, 
with increasing doses from 1 to 1000 nM, TNF-α was incrementally decreased 
compared to the DMSO control, reaching statistical significance at the 100 nM 




The same inhibitory effect of IκK-16 was observed with respect to IL-10 levels. 
There was more variability in IL-10 production between donors, but IκK-16 
treatment decreased IL-10 production at doses of 100 nM (p = 0.078) and 
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IκK-16 is a selective inhibitor of IκK. Following isolation of monocytes, cells 
were divided into either 100 nM IκK-16 (which is diluted into a very low 
concentration of DMSO) or control with DMSO only for 1 h. IκK-α/β 
phosphorylation was determined by Western Blot after the addition of 100 
ng/mL LPS (given at 1 h). Beta-actin was used as a loading control. IκK-16 
effectively decreases IκK phosphorylation, shown as a representative Blot (A) 
and quantitatively using four different donors (B). * p < 0.05, Paired T-test.   
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Monocytes cultured with IκK-16 (diluted in DMSO) at various doses for 1 h, 
then stimulated with 100 ng/mL LPS for 16 h. At this point, cells were stained 
with Trypan Blue and manually counted by standard microscopy for number of 
viable cells, expressed as a percentage of the initial cell number. This 
experiment demonstrates that neither DMSO nor IκK-16 is toxic to human 
monocytes. Four donors were used for these experiments. “ – “ denotes the 
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Figure 31. Effect of IκK-16 on TNF-α production.  
  
Monocytes were cultured with IκK-16 at various doses (diluted in DMSO) for 1 
h, then stimulated with 100 ng/mL LPS until 17 h. At 17 h, cell culture 
supernatant was measured for TNF-α protein concentration by ELISA. Both 
100 nM and 1000 nM doses of IκK-16 were effective in decreasing TNF-α 
production (p < 0.05, ANOVA with post-hoc Tukey Kramer test). N = 4.  
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Figure 32. Effect of IκK-16 on IL-10 production.  
 
Monocytes were cultured with IκK-16 at various doses (diluted in DMSO) for 1 
h, then stimulated with 100 ng/mL LPS until 17 h. At 17 h, cell culture 
supernatant was measured for IL-10 protein concentration by ELISA. 
Compared to 1 nM, the 1000nM dose decreased IL-10 levels (* p < 0.05). The 
100 nM dose also appeared to decrease IL-10 levels compared with 1 nM, 
approaching significance at 0.078 (#, ANOVA with post-hoc Tukey Kramer 
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Effect of IκK-16 on HLA-DR expression 
Isolated monocytes were stimulated with or without IκK-16 for 1 hour, before 
the 100 ng/mL LPS challenge was added for 16 hours to determine the effect 
of IκK on HLA-DR expression. We found no differences in the levels of HLA-
DR expression between those treated with or without IκK-16, demonstrated in 
Figure 33. This is clear from quantitative data from 6 donors, but also shown 
qualitatively by scatterplots and histograms produced by flow cytometric 
analyses.  
MicroRNA expression in the impaired monocyte 
Screening experiments were undertaken to examine the expression of 384 
different microRNAs between the naïve and impaired monocyte. Initial 
experiments were undertaken at the 33 hour time point (which equates to 16 
hours after the 100 ng/mL LPS challenge). Significantly dyregulated miRNA’s 
included miRNA-487a, -433, -655 and -450a. Those approaching significance 
with biological significance included miRNA-210, -19b, -29b, -9, -7a, -221 and 
-16. However, verification with single assay miRNA verification did not 
demonstrate any of these to be significantly dysregulated (data not shown). 
Further screening was undertaken at the earlier 17 h time point (i.e. the time 
of the 100 ng/mL LPS challenge).  These results revealed that miRNA-155 
was the most consistently dysregulated, with miRNA-214 and miRNA-519e 
also reaching statistical significance (Figure 34).  Those approaching 
statistical significance were therefore included for single assay experiments 
and included miRNA-10a, -885-5p, -362-3p, -150, -133b, -138, and -212. 
However, on single assay verification, only miRNA-155 was significantly 




Both naïve and impaired monocyte expression of miRNA-155 was 
upregulated when compared against baseline levels, but low dose 10 ng/mL 
LPS resulted in a additive increase  to a 12 fold increase compared to 
baseline, pre-LPS levels.   
Effect of IκK-16 on miRNA-155 expression 
We have already shown that miRNA-155 expression increases in response to 
LPS. When monocytes were treated with 100 nM IκK-16 for 1 hour prior to 
100 ng/mL LPS stimulation, miRNA-155 was suppressed compared to control 














Monocytes were cultured in conditions of either no IκK-16/no LPS, no IκK-
16/LPS or IκK-16/LPS for 17 h. Cells were analyzed using flow cytometry for 
HLA-DR expression using a fluorescent PE stain (read on an FL2 channel). 
Measurements were taken at the time of isolation and at 17 h. In standard cell 
culture conditions, HLA-DR expression increases by 17 h from baseline 
levels. Inhibition of IκK by IκK-16 does not influence HLA-DR expression (i). N 
= 6. This is shown qualitatively (ii) with scatterplots comparing 100 ng/mL LPS 
only vs.  100 ng/mL LPS + 100 nM IκK-16, and via a representative histogram 
demonstrating no effect if IκK inhibition on HLA-DR (light gray = LPS only, 
dark gray = IκK-16/LPS).  
Hours after 
isolation 
0 17 17 17 
100 ng/mL LPS - - + + 































 Figure 33B. Effect of IκK-16 on HLA-DR expression (ii). 
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Light gray = LPS only 
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After 1 h rest, monocytes were cultured for 16 h in either media only (naïve) or 
10 ng/mL LPS. At 17 h, cells were collected and lysed before RNA was 
extracted. Following reverse transcription, Taqman Low Density Array cards 
were used to measure the relative expression of 384 miRNAs by qRT-PCR. A 
combination of RNU6, RNU44 and RNU48 were used as housekeeping genes 
for normalization. MiRNA expression in the impaired monocytes were 
compared to naïve monocytes as their control to express fold changes. Dots 
to the right (red) represent upregulated miRNAs, whereas dots on the left 
(green) represent downregulated miRNAs within the impaired monocyte. 
Paired T-tests were used to generate –log10 p-values. A log10 p-value of 1.3 is 
equivalent to 0.05, thus miRNAs above this level were considered significant.  
N = 5.  
N = 5  
















































MiRNAs that were significant and approaching significance from the miRNA 
screening were included for single assay qRT-PCR analysis to verify 
differences in expression between naïve and impaired monocytes at 17 h. 
Fold changes here are calculated relative to the baseline level of miRNA 
expression at isolation. MiRNA-155 is upregulated in both conditions during 
the 17 h of cell culture, but low dose 10 ng/mL LPS results in even greater 
increase (#  p = 0.08). Other miRNAs assessed were not significantly different 
between conditions.   
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Monocytes in culture following 1 h of rest were either stimulated with 100 
ng/mL LPS only (green) or 100 ng/mL LPS in combination with 100 nM IκK-16 
for 17 h. At 17h, monocyte intracellular RNA was extracted and miRNA-155 
expression was determined by qRT-PCR. MiRNA-155 levels are expressed 
relative to control (100 ng/mL LPS + dilute DMSO only). This shows that IκK-
16 blocks miRNA-155 production in response to LPS (* p <0.05, Paired T-




































This chapter aimed to understand the mechanisms underpinning how an initial 
stimulus leads to a subsequent suppressed inflammatory response. The 
hypothesis was that alteration of NFκB and IκK signaling account for how 
impaired monocytes have suppressed immune responses. The first set of 
experiments in this chapter demonstrate decreased levels of total p65, the 
active subunit of NFκB, decreased p65 phosphorylation and critically, 
impaired IκB degradation. The three sets of data examine different measures 
of NFκB functionality and all demonstrate alterations in this important pro-
inflammatory pathway. NFκB is known to be stimulated by LPS and other TLR 
ligands in order to generate an inflammatory response. It has been 
established that LPS activates NFκB to produce TNF-α, which occurs within 
the first 17 hours. In response subsequent LPS challenge, the data presented 
here show that cells with prior LPS exposure have suppressed NFκB 
activation, decreased gene expression of TNF-α and decreased TNF-α 
production. This suggests a negative feedback loop presumably evolved to 
protect excessive, ongoing and potentially harmful responses. Recall the early 
experiments by Beeson in the 1950’s, which showed that repeated endotoxin 
injections to dogs produced less and less of a fever after each exposure. 
NFκB suppression would also account for the decreased IL-6 and IL-10 levels 
also seen in the previous chapter, as these genes are known to be 
transcribed via this signaling pathway. It should be noted that other pathways 
exist in pro-inflammatory responses. We have not examined MAPK or 




The most compelling experiments demonstrate decreased IκB 
degradation in the impaired cells. This molecule represents “the brakes” within 
this pathway, which in essence “are left on”. In a normal response, the brakes 
are released by the upstream kinase, IκK. Therefore, these results imply that 
there may be suppressed IκK function which might account for this defect.  
Our experiments began focusing on the gene expression of the 
catalytic subunits, IκK-α and –β. Recall that in the Glue Grant studies 
discussed earlier, IκK-β was downregulated in trauma patients compared to 
healthy controls. Our results do not show differences in IκK-β gene expression 
or indeed protein levels in the impaired monocyte. Conversely, IκK-α was 
consistently downregulated in the impaired monocyte in terms of gene 
expression. However, this difference was not proven in the protein levels at 17 
hours. Time course Western Blot experiments did not convincingly show 
differences in IκK-α at later time points. It is not uncommon that differences in 
messenger RNA are not always shown with the protein product. One possible 
explanation for this may be the persistence or lack of degradation of the 
existing protein product within the cells (in essence, changes in the production 
but not changes in the degradation).  
Given the lack of evidence for decreases in the total concentrations of 
the catalytic subunits of IκK, the next experiments examined the level of 
activation, i.e. level of phosphorylation of IκK, in response to the 100 ng/mL 
LPS challenge. Western Blots every 15 minutes after the challenge revealed 
clear suppression of IκK phosphorylation in cells with prior LPS exposure, 
when compared to naïve cells that demonstrated dynamic IκK 




Indeed, these experiments address the hypothesis that IκK is suppressed in 
the impaired cells. However, they demonstrate correlation, but do not in 
themselves prove causation, which we will address later.  
 Given that the “chain of activation” via a cascade of 
phosphorylation has been interrupted and prevented signals downstream, we 
explored upstream mechanisms. TAK-1 is often described as an intermediate 
signaling protein between TLR pathways and IκK. However, our experiments 
do not show any differences in the phosphorylation or total levels of TAK-1 
between naïve and impaired monocytes. One should note that TAK-1 is 
known to be affected by ubiquitination in very complex biochemical protein 
modifications, which we did not examine as this was beyond the scope of the 
hypothesis. Furthermore, the input signals from upstream pathways to IκK are 
redundant and involves more than 15 modifiers including a multitude of 
kinases and phosphatases. Therefore, we adopted an approach of examining 
a large amount of TLR related genes using gene expression profiling 
experiments comparing the impaired monocyte to the naïve. We found that 
TRAF-6, a gateway to numerous downstream pathways including NFκB, was 
decreased. TRAF-6 has previously shown to be decreased in endotoxin 
tolerance type studies, and more recently has been attributed to post-
translational modification by TNFAIP3 (A20) and miRNA-146a, and is thought 
to be induced in response to the initial LPS stimulus. Even more interesting is 
the findings of decreased TRAF-6 in the impaired monocyte in the TLR 
profiling experiments. This may in fact reveal a signaling defect between 




Other interesting trends included the downregulation of NFκBIA and 
CD14. The former represents a gene coding for a subunit of the IκB complex. 
This is in contrast to expected findings, as in albeit very different models 
studying TNF signaling, IκB was in fact upregulated in response to external 
TNF stimulation in order to limit later NFκB activation. However, a trend 
towards decreased CD14 gene expression would correspond with decreased 
responses to subsequent LPS stimulation, as CD14 is a co-receptor with MD2 
and allows for TLR4 dimerization and signal transduction to MyD88. This 
represents potentially multiple levels of negative feedback regulation, which 
demonstrates the redundant nature of the innate immune system.  
It should also be noted that there are various other explanations for the 
decreased responsiveness to LPS. Rather than intra-cellular molecular 
feedback mechanisms, an internalization of surface membranes and a 
change in plasma membrane fluidity could result in the lack of available 
external receptors for LPS, resulting in an impaired response. In addition, this 
impairment could also be explained by a failure to recruit TLR4 receptors form 
the cytosol, or other  structural “machinery” which is exhausted. This was 
certainly beyond the scope of this dissertation, but is an interesting area for 
future research.  
Our attention turned back to the role of IκK in monocyte function. There 
is a correlation between decreased IκK phosphorylation, decreased pro-
inflammatory cytokines and decreased HLA-DR expression in the impaired 
monocyte. If monocyte impairment occurs as a result of IκK signaling, we 
wanted to see if IκK inhibition would “turn a naïve monocyte into an impaired 




phosphorylation. Other studies have demonstrated decreased IκK 
phosphorylation in response to IκK-16. We confirm these findings in Figure 
29, which demonstrates a true loss of function with use of this small molecule 
selective inhibitor. This is of interest not only to demonstrate the mechanistic 
role of IκK, but IκK-16 has been investigated as a potential therapy for 
excessive inflammation in animal models of sepsis and hemorrhagic shock. 
Importantly, any differences seen are due to pathway inhibition, rather than 
toxicity to cells (Figure 30). Indeed, inhibition of IκK decreases both TNF-α 
and IL-10 production, as seen in the impaired monocyte, in a dose-dependent 
fashion. This proves a cause and effect relationship between the suppression 
of IκK and pro-inflammatory cytokine production, as per the thesis hypothesis. 
100 nM IκK-16 appears to be the minimal dose for therapeutic effect.  
The same was not true for IκK inhibition and HLA-DR expression. 
Despite exposure to the same dose of IκK-16 (100 nM) shown to effectively 
decrease activation of IκK, there was no change in HLA-DR expression 
compared to control. The expression of HLA-DR has been mostly attributed to 
transcription of CIITA following JAK-STAT1 signaling, which is known to be 
activated by IFN-γ. However, cross-talk between STAT and NFκB pathways 
does exist, with LPS induced HLA-DR activation previously shown to also 
depend on NFκB activation 116. Taken together, it is therefore possible that 
there are defects of JAK-STAT signaling in impaired monocytes that 
contribute to decreased HLA-DR expression, rather than a direct result of 
decreased IκK and NFκB signaling. This has very interesting clinical 
implications. The use of “blockers” of the inflammatory response of course 




However, these experiments suggest that IκK-16 has the potential to be used 
as a “dimmer switch” to tune down inflammatory cytokine production but still 
preserve antigen-presenting functions, as measured by HLA-DR expression. 
These findings in combination with those by Li et al who found that IκK-16 did 
not impair phagocytosis suggest that IκK-16 would decrease cytokine 
responses by monocytes but not the other functions such as antigen 
presentation and phagocytosis.  
MiRNAs are small, non-coding single stranded RNA sequences in their 
mature form which cause post-transcriptional inhibition of protein production. 
There has been a great deal of research into the role of miRNA in a variety of 
diseases including cancer and inflammation-related conditions. MiRNAs are 
known to act as powerful regulators of toll-like receptor signaling, and other 
groups have shown that miRNA-146a is increased in conditions of endotoxin 
tolerance. In our findings, there was a slight increase in miRNA-146a in the 
impaired monocytes, but this was not consistent and the magnitude of the 
change was very small, which therefore did not qualify for single assay 
verification. By comparison, miRNA-155 was upregulated in both naïve and 
impaired conditions, but more so in the impaired condition. It has been shown 
previously that miRNA-155 is increased in response to TLR ligands such as 
LPS 117, but has not been associated with impaired monocyte function in the 
same way as miRNA-146a. More commonly in the literature, miRNA-155 is 
known for its early pro-inflammatory actions through suppressing its targets of 
SHP1 and SOCS1 to promote TNF-α and other pro-inflammatory cytokines. 
However, the delayed effects of miRNA-155 in decreasing the pro-




related targets also include RelA (p65), MyD88, TAB2 (part of the TAK-1 
complex) and IκK-ε and would explain the role of miRNA-155 in dampening 
inflammation. Of those targets measured in our experiments, p65 was 
decreased as assessed by Western Blot at 60 minutes after the LPS 
challenge, and IκK-ε trended downward in TLR profiling of the impaired 
monocyte, in keeping with these miRNA-155 results. Given the higher 
expression of miRNA-155 in the impaired monocyte and the decrease in 
miRNA-155 targets, this could in part explain the suppression of IκK and 
monocyte function in general. Nevertheless, miRNA-155 is associated with a 
large number of inflammatory diseases and previous research in our lab 
demonstrated the important role in cytokine regulation 54. MiRNA-based 
therapy may be possible in the future, however, in the meantime 
understanding how current therapeutics may influence miRNA expression as 
a mechanism of action improves our understanding of positive and negative 
effects of therapy. Our results demonstrate that IκK inhibition with IκK-16 
decreases miRNA-155 expression. This demonstrates mechanistically that 
miRNA-155 induction is IκK dependent, and that a likely feedback loop exists 
in our model involving LPS stimulation of IκK and subsequent miRNA-155 
induction in the first 17 hours, which in turn inhibits TLR, IκK and NFκB 
activation in response to the LPS challenge through miRNA-155 mediated 
inhibition of p65 and the other discussed targets. These results also imply that 
IκK-16 therapy could limit excessive early inflammatory responses (via 
decreasing the inhibition from SOCS1 and SHP1), and limit delayed 




 The miRNA screening experiments were designed to “throw the net 
wide” in an unbiased fashion to find potentially novel miRNAs in the context of 
monocyte impairment. However, this approach has some limitations. We 
measured time zero (after isolation), at 17 hours and at 33 hours. It is possible 
that we may have missed some miRNAs which were transiently changed 
between these time points. Furthermore, the screening approach carries the 
risk of both false positive and false negative results. Ideally, if there were a 
higher number of donors used for screening with larger magnitudes of miRNA 
differences, a false-discovery rate (FDR) correction such as the Benjamini-
Hochberg procedure or the method of Jung may have been appropriate to 
limit the risk of type I error 118,119. Future studies with gain and loss of function 
of miRNA-155 would be interesting, however this was beyond the scope of 
this project and given the relatively small differences of miRNA-155 
expression between conditions we turned our attentions downstream in the 
pathway, as discussed in the next chapter.  
  In summary, this chapter  has focussed on IκK signaling and 
demonstrated that 1) Impaired monocytes have decreased NFκB activation, 
2) Impaired monocytes have decreased IκK phosphorylation 3) naïve cells 
can become “impaired” by IκK inhibition in terms of cytokine production 4) IκK 
inhibition does not impair HLA-DR expression. These results demonstrate 
cause and effect of IκK function and the capacity of the monocyte to produce 







THE ROLE OF IΚK IN THE INFLAMMATORY RESPONSE 
INTRODUCTION 
 
Our data thus far demonstrates the critical role of IκK activation and the 
monocyte inflammatory response. Our results have focused on TNF-α, IL-10 
and HLA-DR as markers of monocyte function. However, as increasingly 
complex assays are applied to studying sick surgical patients, a long list of 
cytokines and markers have been associated with poor outcomes in the 
surgical patient following trauma.  
 Certain patterns of cytokine and chemokine levels in patients following 
major trauma have been shown to predict patient trajectories 120. In a study by 
the Pittsburgh group, 44 patients who developed nosocomial infection after 
trauma were compared to 44 patients who had an uncomplicated recovery. 
Patient cohorts were matched by age, gender, injury severity score and 
interventions. Both groups had increases in MCP-1 (CCL2), IL-6, IL-1RA and 
HMGB1 compared to healthy volunteers, but levels were higher in the group 
who became infected.  Those who suffered later infection also had early and 
sustained increases in IL-7, IL-5, IL-17A, IL-4, IL-13, MIP-1α (CCL3), MIP-1β 
(CCL4), IFN-γ, IL-15, sIL-2Rα, GM-CSF and IP-10. In sequential observations 
of both sets of trauma patients, levels of IFN-α, IL-1β, IL-2 and TNF-α were 




infection, these levels gradually rose by 24 hours, with persistent elevation up 
to 7 days after injury. It should be noted that in this study, the mean time to 
developing infection was 7 days following injury (i.e. after the observed 
cytokine changes), which suggests that the infection may be a consequence 
of immune dysregulation, rather than the reverse.  
The aims of this experiment were 1) to determine whether specific 
cytokines were inhibited in the context of monocyte impairment, or whether a 
global reduction in the capacity to produce cytokines occurs and 2) to 
determine which cytokines and chemokines were modulated through IκK 
inhibition, to offer a better understanding of this potential therapeutic target.  
METHODS 
Sample size considerations 
Power calculations were undertaken based on prior pilot experiments with 
data on TNF-α, IL-10 and IL-6 as representative cytokines. The effect size 
was estimated based upon the mean differences and variability of that 
difference between the naïve and impaired monocyte at 12 hours following 
the 100 ng/mL LPS challenge (Table 5A). This was then used to estimate the 
required sample size, depending on the minimal detectable difference for the 
three cytokines (Table 5B). A representative power-sample size curve for IL-
10 is shown (Figure 37). Based on these calculations, 10 different donors 
were used for these experiments in order to achieve a power of 0.80 (80%). 
Non-parametric analysis was used to determine power and sample size 




subsequent data sets). This demonstrated increased power in the preliminary 
data (70-85%).  
 
Assay quality and detectability 
 Twenty-nine different cytokines and chemokines were measured in the 
cell culture supernatant using a magnetic-bead based protein assay. Each of 
the 96 wells tested had over 50 beads per cytokine, exceeding the minimal 
count required for assay reliability. Two sets of quality controls were used to 
measure expected levels for each of the 29 parameters, which all fell within 
the expected range. Samples were run in duplicate. IL-3 levels were below 
the lower limits of detection; IL-6 and MIP-1α concentrations were above the 
upper limits of detection and could not accurately be interpreted. IL-6 was 
therefore run separately as an individual ELISA. The experimental design is 




Table 5. Power and sample size calculations for the multiplex cytokine 
analysis.  
Table 5A.  
*Non-parametric power calculation based on Wilcoxon signed rank test & 
subsequent Z-test on ranks.  
Table 5B.  
*Non-parametric estimate of sample size based on noncentrality parameter 
and expected differences from ranks. 
Preliminary data of differences in TNF-α, IL-10 and IL-6 between naïve and 
impaired monocytes at after the 100 ng/mL LPS challenge (12 hours) is 
shown in Table 5A. The effect size from the preliminary experiments allows 
for a sample size calculation, depending on how much of a difference is 




















(1 – β) 
Power* 
(ranks) 
TNF-α 7 508.1 301.7 206.4 257.8 0.803 0.42 0.70 
IL-10 7 981.5 586.8 394.7 380.1 1.038 0.63 0.85 
IL-6 7 6659.1 3545.7 3113.4 3228.7 0.964 0.57 0.85 
α 
Power 














0.05 0.80 If 100: 0.388 55 
11.4 0.05 0.80 If 200: 0.826 16 
0.05 0.80 If 300: 1.164 8 
IL-10      
0.05 0.80 If 200: 0.526 31 
4.6 0.05 0.80 If 400: 1.052 10 
0.05 0.80 If 600: 1.578 6 
IL-6      
0.05 0.80 If 1500: 0.464 39 
4.6 0.05 0.80 If 3000: 0.929 12 




Figure 37. Power-sample size graph based on IL-10 differences between 




Sample size calculations were plotted against power. This representative plot 
demonstrates the sample size for IL-10 at 12 hours following an LPS 
challenge, comparing naïve and impaired monocytes. Note that as the sample 
size increases, the power of the test obviously increases. A sample size of 10 
donors would allow for an experiment to have a power of over 0.8 (80%).  











Monocytes were cultured in 4 conditions. In the first 17 hours, cells were 
treated either with media only (1, unstimulated negative control and 2, naive), 
low dose 10 ng/mL LPS (3, impaired) or with 100 nM IκK-16 (4, IκK inhibited) 
all given at 1 hour after isolation. After 17 hours, cells were resuspended in 
fresh media and were cultured either with media only (1, unstimulated 
negative control) or 100 ng/mL LPS challenge (2, naïve, 3, impaired and 4, 
IκK inhibited monocytes). At 29 hours (12 hours after 100 ng/mL LPS 
challenge), concentrations of cytokines and chemokines in cell culture 
supernatants were determined by a Milliplex Human Cytokine/Chemokine 29-







In response to the 100 ng/mL LPS challenge, naïve monocytes produced 
higher levels of TNF-α, IL-1β, IL-6 and IL-12 compared to the unstimulated 
control (Figure 39). There were no increases in IL-8 production following LPS 
treatment. Impaired monocytes, which had prior stimulation with low dose 10 
ng/mL LPS, had a decreased capacity to produce TNF-α, IL-1β and IL-6 
compared to the naïve control. There was also small reduction in IL-12p70 
production by impaired monocytes.  
IκK inhibition by IκK-16 treatment led to a decrease in TNF-α, IL-12 and IL-8, 
with profound suppression of IL-1β and IL-6 levels compared to naïve cells.  
One should note that IL-6 levels higher than the upper limits of detection of 
the Milliplex assay were observed, and were therefore then separately tested 
by individual IL-6 ELISA  at an appropriately higher dilution and similarly 
analyzed.   
Anti-inflammatory cytokines 
Levels of the anti-inflammatory cytokines IL-1RA and IL-10 were increased 
with LPS stimulation in the naïve cells compared to the unstimulated negative 
control, whereas levels of IL-4 and IL-13 were unchanged (Figure 40). 
Monocyte impairment led to decreases in IL-10 production, but IL-1RA, IL-4 
and IL-13 levels were similar between naïve and impaired conditions.  
Inhibition of IκK decreased the levels of IL-10, IL-4 and IL-13. Levels of IL-




Figure 39. Effects of monocyte impairment and IκK inhibition on pro-

















































































































Legend for Figure 39.  
 
Monocytes were cultured in either media only, low dose 10 ng/mL LPS or IκK-
16 (100 nM) for 16 hours. Cells then either remained unstimulated 
(Unstimulated), or received 100 ng/mL LPS challenge (Naïve, Impaired, IκK-
16) for 12 hours after the LPS challenge. Cell culture supernatants were 
measured using a Human Cytokine/Chemokine Milliplex assay. Results for 
pro-inflammatory cytokines are shown using 10 donors, compared using 
Wilcoxon Signed rank Test. * p <0.05, ** p < 0.01. Please note IL-6 was run 
separately by individual ELISA due to high levels observed in the Milliplex 




Figure 40. Effect of monocyte impairment and IκK inhibition on anti-















Legend for Figure 38.  
 
 
Monocytes were cultured in either media only, low dose 10 ng/mL LPS or IκK-
16 (100 nM) for 16 hours. Cells then either remained unstimulated 
(Unstimulated), or received 100 ng/mL LPS challenge (Naïve, Impaired, IκK-
16) for 12 hours after the LPS challenge. Cell culture supernatants were 
measured using a Human Cytokine/Chemokine Milliplex assay. Results for 
anti-inflammatory cytokines are show using 10 donors, compared using 
Wilcoxon Signed rank Test. * p <0.05, ** p < 0.01. 
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MIP-1β levels increased in response to LPS in naïve cells, with a very small 
increase in the levels of another chemokine called eotaxin (Figure 41). IP-10 
levels were not increased by LPS stimulation and, interestingly, MCP-1 levels 
actually decreased slightly compared to unstimulated monocytes.  
10 ng/mL LPS treatment resulted in suppressed MIP-1β, MCP-1 and IP-10 
levels in response to the 100 ng/mL LPS challenge, with eotaxin levels 
unchanged in impaired cells compared with naive.  
IκK-16 treatment decreased the levels of MIP-1β, MCP-1 and eotaxin 
compared to naïve monocytes. Unexpectedly, monocytes with IκK inhibition 
actually increased IP-10 production by approximately ten fold in response to 
the 100 ng/mL LPS challenge compared with naïve monocytes.   
MIP-1α levels were above the upper limits of detection of the Milliplex assay 
and therefore were excluded from analysis.  
Growth Factors 
Naïve monocytes produced higher levels of G-CSF, GM-CSF and also VEGF 
in response to 100 ng/mL LPS challenge, compared to unstimulated control 
cells. In monocytes with low dose 10 ng/mL LPS impairment, the capacity to 
produce GM-CSF, and to a degree VEGF, was reduced. Impaired monocytes 
could produce equivalent concentrations of G-CSF and EGF.  
IκK-16 treatment decreased the production of all four of these growth factors, 




Figure 41. Effects of monocyte impairment and IκK inhibition on chemokine 















Legend for Figure 38.  
 
 
Monocytes were cultured in either media only, low dose 10 ng/mL LPS or IκK-
16 (100 nM) for 16 hours. Cells then either remained unstimulated 
(Unstimulated), or received the 100 ng/mL LPS challenge (Naïve, Impaired, 
IκK-16) for 12 hours. Cell culture supernatants were measured using a 
Human Cytokine/Chemokine Milliplex assay. Results for chemokines are 
shown using 10 donors, compared using Wilcoxon Signed rank Test. * p 
<0.05, ** p < 0.01.  
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N = 10 for all  
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Monocytes were cultured in either media only, low dose 10 ng/mL LPS or IκK-
16 (100 nM) for 16 hours. Cells then either remained unstimulated 
(Unstimulated), or received 100 ng/mL LPS challenge (Naïve, Impaired, IκK-
16) for 12 hours after the LPS challenge. Cell culture supernatants were 
measured using a Human Cytokine/Chemokine Milliplex assay. Results for 
growth factors are shown using 10 donors, compared using Wilcoxon Signed 
rank Test. * p <0.05, ** p < 0.01.  
GM-CSF
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Other immunoregulatory cytokines 
The 100 ng/mL LPS challenge increased the levels of IFN-α2, IL-2 and IL-7, 
compared to unstimulated cells. Impaired monocytes produced decreased 
levels of IFN-α2, IL-7 and TNF-β compared to naïve cells, whereas IFN-γ, IL-
15, IL-17 and IL-2 were unchanged between these naïve and impaired 
conditions. Interestingly, IL-1α was the only cytokine or chemokine tested 
which was elevated in the impaired cells compared to naïve conditions. IκK 
inhibition led to a reduction in IFN-α2, IFN-γ, IL-15, IL-17, IL-1α, IL-2, IL-7 and 
TNF-β levels compared to naïve monocytes (Figure 43). It should be noted 
that in all four conditions (unstimulated, naïve, impaired and IκK-16 treated), 
levels of IL-15, IL-17 and IL-2 were detectable but below 10 pg/mL. IL-5 levels 
were below the minimal detectable concentration of 3.2 pg/mL, and IL-3 levels 
were completely undetectable.  Results for all cytokines/chemokines are 





Figure 43. Effect of monocyte impairment and IκK inhibition on other 
immunoregulatory cytokines.  
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Monocytes were cultured in either media only, low dose 10 ng/mL LPS or IκK-
16 (100 nM) for 16 hours. Cells then either remained unstimulated 
(Unstimulated), or received 100 ng/mL LPS challenge (Naïve, Impaired, IκK-
16) for 12 hours after the LPS challenge. Cell culture supernatants were 
measured using a Human Cytokine/Chemokine Milliplex assay. Results for 
other immunoregulatory cytokines are shown using 10 donors, compared 
using Wilcoxon Signed rank Test. * p <0.05, ** p < 0.01. 
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An additional, more complex statistical analysis was undertaken on the 
Milliplex cytokine/chemokine data. Given the large variability from donor to 
donor for a given protein and the large variability between the actual raw 
levels from protein to protein, this analysis was designed to address these 
issues to allow cytokine patterns to be compared against one another.  
In this analysis, the primary endpoint was the within-subject protein relative 
change from the Naïve condition to the Impaired condition. Relative change 
within subject samples was defined as: 
                                       
                                   
. To 
ensure the endpoint was approximately normally distributed, the endpoint was 
log (base 2) transformed. Student’s t-test were then performed with the null 
hypothesis that the average log relative change was equal to 0 (no difference 
across condition) versus the alternative hypothesis that average log relative 
change was not equal to 0. As multiple comparisons (proteins) were made, q-
values for preserving the False Discovery Rate (FDR) as opposed to the 




      where      represents expected value,   is the number of Type I 
errors (false positives) and   is the number of rejected null hypotheses 121. As 
an example, if differences with        are deemed “significant” then on 
average 5% of these tests are false positives. Q-values were computed using 
the method developed by Storey 122.  
This data is shown in Figure 44 and demonstrates that TNF-α was the most 
diminished of all cytokines and chemokines measured, and appeared to be 




resulting from monocyte impairment. In addition, the findings demonstrate that 
numerous chemokines (green) which are significantly downregulated  (i.e. 




Figure 44. Relative change of cytokine & chemokine production in the 
impaired monocyte compared to the naïve cells (Secondary analysis).  
 
The relative changes of each cytokine/chemokine from naïve to impaired 
monocytes are summarized here. Each dot represents a within-subject 
relative change. Stars denote statistical significance. *:q < 0.05 **: q < 0.01. 
(Q-values are a measure of significance reflecting the false positive rate that 
accounts for multiple comparisons). Colors denote the function of each protein 
(e.g. pro-inflammatory). Proteins are ordered top to bottom based on the 
relative change in the impaired monocyte, from most increased cytokine in the 
impaired (IL-1α) down to the most decreased cytokine at the bottom (TNF-α).  
Secondary analysis was with undertaken with the help of P. Trainor (PhD 
candidate, Statistics).   





A critical balance is required to ensure a sufficient innate response to prevent 
as well as clear infective challenges to the body, but also to limit an excessive 
systemic inflammatory response to prevent ongoing damage and tissue 
destruction. In the context of critical illness in the surgical patient, this balance 
is often lost. Too much or too little of any aspect of the immunological system 
has the potential for undesirable consequences. For that reason, the concept 
of immune modulation carries a risk; “turning off” the immune system following 
trauma or during sepsis risks nosocomial infection and failed pathogen 
clearance, and “amplifying” the immune response could risk unnecessary 
fever and systemic inflammation. This chapter deals with two of these 
considerations; 1) during conditions of monocyte impairment resulting from 
prior low dose endotoxin stimulation; which aspects of cytokine and 
chemokine production are deficient, and which are preserved? 2) Focused, 
specific inhibition of IκK may decrease TNF-α production but what other 
cytokines and chemokines are dependent on this pathway? How similar are 
these two phenomena?  
 The present experiments were designed with sample size calculations 
based upon prior pilot experimental data. Ensuring a study is powered 
sufficiently should reduce the risk of type II error and missing a potentially 
significant result. Although these calculations were based on TNF-α, IL-10 
and IL-6 from prior to the experiments, we cannot guarantee that all cytokines 





 Endotoxin stimulation of naïve monocytes resulted in a measurable 
increase in over 15 inflammatory mediators, which included pro-inflammatory 
and anti-inflammatory cytokines, as well as numerous chemokines. Some of 
these, such as IL-2, IL-15 and IL-17 were low and although above the lower 
limits of detection, should be interpreted with caution. By contrast, the levels 
of production of IL-6 and MIP-1α by naïve monocytes were above the upper 
limits of detection and therefore were excluded for analysis. IL-6 was 
consequently tested separately by individual ELISA, and it is this IL-6 data 
which is shown. In addition, whilst IL-8 was within range, I believe that these 
should also be interpreted with caution as the unstimulated, naïve and 
impaired conditions were similar at 14,000 pg/mL. It is possible that LPS 
stimulation increased IL-8 levels beyond that of the unstimulated cells, and 
levels from the impaired monocyte may be lower than naïve levels, which may 
not be reflected in our results. It should be noted that similar to previous 
experiments, the unstimulated monocytes have relatively high levels of many 
inflammatory mediators which is likely a function of cellular stimulation from 
the isolation procedure and centrifugation steps.  
 Prior results in this dissertation have indicated that TNF-α, IL-6 and IL-
10 were important inflammatory cytokines that were suppressed in the 
impaired monocyte. In this different assay platform, TNF-α, IL-10 and IL-6 
were again all decreased compared with naïve cells, which confirms the 
previous results. These data show the impaired monocyte also has a 
decreased capacity to produce IL-1β, IL-12p70, MIP-1β, MCP-1, GM-CSF, 
VEGF, IFN-α2, TNF-β and IL-7. The identification of these inflammatory 




growth factor production by the monocyte are functions that are also  to some 
degree impaired. This would add further explanation to the decreased 
pathogen clearance seen in such patients, due to decreased leukocyte 
chemoattraction, as well as the lack of maturation and differentiation of new 
circulating leukocytes such as myeloid-derived suppressor cells 123,124. Many 
pro-inflammatory cytokines are produced in response to NFκB activation, thus 
a reduction in all of these pro-inflammatory cytokine responses after IκK-16 
was expected.  
 Anti-inflammatory cytokines are important mediators in resolving 
inflammation after an initial insult, but excess levels can themselves suppress 
other genes. LPS effectively increases IL-1RA and IL-10, but only IL-10 was 
suppressed in the impaired monocyte compared to the naïve cells. This 
supports the notion that global functions were impaired, rather than a 
polarization of monocytes and macrophages toward an “M2” phenotype, 
where higher IL-10 levels would be expected. The significance of the 
decrease in anti-inflammatory cytokines following IκK inhibition (with IκK-16) is 
that this may “maintain the balance” with the reduced pro-inflammatory 
cytokines, preventing a dominance of these anti-inflammatory mediators. 





Figure 45. Summary of the effect of monocyte impairment and IκK inhibition 
on cytokine and chemokine networks (as per the primary analysis).  
 
Low dose LPS 10ng/mL results in monocytes having an impaired capacity to 
produce a large number of cytokines and chemokines (red). Specific inhibition 
of IκK, a central feature of monocyte impairment, results in decreased levels 
of all cytokines and chemokines seen in blue. Those inflammatory mediators 
which are decreased in both conditions are shown in the central region where 
the two networks overlap. Cytokines that were undetectable are not shown. 
MCP-1 is the only mediator which is decreased in monocyte impairment but 
not influenced by IκK inhibition. IP-10 is also decreased in monocyte 
impairment, but increases during specific IκK inhibition. IL-1α was the only 
mediator which was increased in monocytes impaired by prior 10 ng/mL LPS 




 MCP-1, also known as monocyte chemoattractant protein-1 or CCL2, 
yielded some interesting findings. MCP-1 has previously been described as 
having a central role in injury-induced inflammation 125. This was the only 
mediator to decrease in response to the 100 ng/mL LPS challenge, and was 
the only cytokine decreased in the impaired monocyte but not regulated by 
IκK signaling. MCP-1 is thought to be governed by JNK and MAPK p38 
pathways, and therefore MCP-1 suppression may suggest alterations in these 
pathways 126. It should be noted that the difference between naïve and IκK-16 
treated monocytes was only p = 0.08.  
 IP-10 (interferon-gamma induced protein-10), also known as CXCL-10, 
is generally secreted in response to IFN-γ with important roles in 
chemoattraction for other leukocytes, and is thought to govern IL-10 
production. In our results, this mediator showed an unexpected pattern. The 
LPS challenge did not influence levels in the naïve monocyte relative to 
unstimulated cells, but levels were decreased in the impaired monocyte. 
Furthermore, it was the only parameter that consistently increased after IκK 
inhibition. This may suggest that that other cytokines, either raised or 
decreased in the first 17 hours, may modulate IP-10 levels rather than directly 
from LPS stimulation. In addition, there is presumably an intermediate 
molecule which normally suppresses IP-10, that is blocked by IκK-16 and thus 
releasing IP-10 production (in other words, “the inhibitor is inhibited”).  IP-10 
had previously been thought to be NFκB-dependent; however these results 
suggest that other pathways are involved in its production 127.  
 IL-1α was the only cytokine which significantly increased in the context 




result, and to my knowledge has not been previously associated with 
monocyte impairment or “endotoxin tolerance”. IL-1α has the capacity to 
stimulate TNF-α, and both are synergistic in their interaction. In these results, 
IL-1α upregulation is in contrast to TNF-α and to IL-1β, which has a similar 
biochemical structure. Monocytes have a unique mechanism of inducible IL-
1α expression through a long non-coding RNA, but some evidence also 
shows that cell death can lead to the passive leakage of cytosolic IL-1α. 
Impaired monocytes have appeared to have similar rates of cell viability to 
naïve cells according to our previous results, although we have not formally 
measured apoptosis. A more likely explanation is that IL-1α is produced as a 
result of the initial 10 ng/mL LPS stimulus in impaired cells, where its release 
is persistent in a well-recognized, feed forward, “self-perpetuating” 
inflammatory loop 124. This loop appears to be successfully interrupted by IκK 
inhibition. 
 Taken together, the results from this set of experiments expand our 
knowledge regarding the extent of impairment of monocyte function, with a 
now extended range of inflammatory mediators in which impaired monocytes 
have decreased capacity to produce and release. The pattern of change in 
the impaired monocyte highlights those cytokines and chemokines are most 
affected in impairment, as demonstrated by the secondary analysis (Figure 
44). There is significant overlap between impaired monocyte function from 
prior LPS exposure and monocytes inhibited by an IκK inhibitor, supporting 
the role of IκK suppression in monocyte impairment (Figure 45). There are a 
considerable number of mediators which are suppressed by IκK, but are not 




LPS as a “sledgehammer” which may result in cross-talk between other 
inflammatory pathways and redundant feedback loops preserving their 
production through non-IκK mechanisms. Another important consideration is 
the potential for “off-target” effects of IκK-16. While it is believed that this 
inhibitor is specific for IκK, as with any drug, it may have unrecognized effects 
such as the inhibition or activation of other pathways in the inflammatory 
response. What is clear from these results is the broad spectrum of 
inflammatory control governed by IκK activation. The Pittsburgh group have 
associated the elevation of at least 15 cytokines or chemokines with later 
nosocomial infection in trauma patients, that we have shown can be 
decreased by IκK-16 120. The magnitude of the increase in pro- and anti-
inflammatory cytokines and chemokines, as well as the magnitude of the 
decrease in adaptive immunity genes predicted poor outcomes in trauma 
patients (Figure 46) 1. The results presented here demonstrate that IκK-16 
has the capacity to attenuate many of these pro- and anti-inflammatory 
cytokines and chemokines, but crucially without further impairment to HLA-DR 






















The genomic response to trauma is not changed by a “second hit” but 
nosocomial infection and mortality are predicted by the magnitude of the 
change after injury. The larger the increase in innate immunity gene 
expression (such as pro- and anti-inflammatory cytokines and chemokines) is 
related to poorer outcomes. In addition, the level of downregulation in 
adaptive immunity genes such as HLA-DR is also predictive of infection and 
mortality. Taken together, our results show that IκK-16 attenuates the 
response in pro- and anti-inflammatory cytokines and chemokines, without a 
reduction in HLA-DR expression. This pattern of modulation makes IκK 
inhibition an attractive therapeutic strategy (blue arrow).  Adapted from Xaio, 





Table 6. Effect of monocyte impairment and IκK inhibition on cytokine 
production. 
Mean (SEM) shown. P-values (1) reflect Wilcoxon signed rank test. P-values (2) reflect 
Repeated Measures ANOVA with Post Hoc Student Newman Keuls test. Arrows reflect the 
direction of statistically significant differences in cytokines/chemokines between indicated 
comparisons.  Cytokines out-with upper and lower detection limits are excluded. IL-6 data 
run as individual ELISA as described.  















Pro-inflammatory cytokines   
TNF-α 405.5 (86.6) 1325.8 (300.6) 671.3 (140.4) 509.8 (115.6) ↓0.002 ↓0.002 <0.05 <0.05 
IL-1α 1205.4 (280.2) 1419.3 (360.7) 2054.8 (522.9) 182.4 (42.5) ↑0.027 ↓0.002 NS <0.05 
IL-1β 683.1 (134.8) 1245.9 (230.0) 1050.5 (253.1) 56.08 (13.8) ↓0.049 ↓0.002 <0.05 <0.05 
IL-12p70 12.2 (1.3) 15.8 (1.7) 14.0 (1.7) 8.63 (1.0) ↓0.010 ↓0.002 NS <0.05 
IL-6 11310.1 (2949.1) 16899.2 (3288.1) 14384.4 (3066.9) 764.6 (314.9) ↓0.010 ↓0.002 <0.05 <0.05 
Anti-inflammatory cytokines   
IL-10 4446.3 (1157.6) 6692.7 (1398.9) 4785.9 (1032.5) 1279.5 (272.1) ↓0.006 ↓0.002 <0.05 <0.05 
IL-1RA 200.8 (32.3) 252.6 (41.3) 215.1 (32.1) 218.3 (55.7) 0.084 0.322 NS NS 
Chemokines   
MCP-1 7647.6 (1238.3) 6770.5 (1219.9) 5287.8 (1156.7) 5482.5 (1153.2) ↓0.002 0.084 <0.05 NS 
MIP-1β 4699.8 (834.2) 7318.2 (1104.8) 5534.1 (835.6) 3524.4 (755.7) ↓0.004 ↓0.004 <0.05 <0.05 
IP-10 116.7 (30.2) 105.2 (31.9) 60.2 (12.9) 1582.2 (455.4) ↓0.020 ↑0.004 <0.05 <0.05 
Eotaxin 25.3 (1.4) 27.3 (1.7) 27.8 (2.1) 21.2 (1.6) 0.625 ↓0.002 NS <0.05 
IL-8 14150.2 (462.5) 14283.3 (597.9) 14000.0 (833.5) 11606.2 (1097.0) 0.492 ↓0.002 NS <0.05 
Growth factors   
G-CSF 3987.7 (997.1) 5121.1 (1234.5) 5199.3 (1160.4) 162.9 (37.8) 0.250 ↓0.008 NS <0.05 
GM-CSF 246.3 (78.8) 384.0 (86.2) 305.9 (69.2) 29.5 (7.5) ↓0.027 ↓0.002 <0.05 <0.05 
EGF 20.9 (1.3) 22.8 (1.7) 23.0 (1.4) 18.3 (1.4) 0.846 ↓0.002 NS <0.05 
VEGF 148.3 (10.8) 175.0 (13.1) 160.1 (12.0) 121.1 (13.2) ↓0.020 ↓0.002 <0.05 <0.05 
Other immunoregulatory cytokines   
IFN-α2 52.4 (4.9) 68.8 (6.0) 59.0 (5.1) 39.2 (4.1) ↓0.004 ↓0.002 <0.05 <0.05 
IFN-γ 34.9 (4.0) 38.8 (3.9) 38.0 (3.6) 19.5 (2.7) 0.695 ↓0.002 NS <0.05 
IL-4 47.5 (4.5) 53.7 (4.8) 53.7 (5.0) 37.0 (3.5) 1.000 ↓0.002 NS <0.05 





Pathway analysis was undertaken to interpret the complex pattern of cytokine, 
chemokine and surface receptor differences between the studied 
experimental conditions representing monocyte functionality. 
Specifically, the MetaCoreTM database (Thomson Reuters) was used to 
determine signaling networks based on significant cytokines and chemokines 
(p < 0.05 from Repeated Measures ANOVA with Post Hoc Student Newman 
Keuls test between naïve and impaired monocytes) and HLA-DR (deemed to 
be significantly different as per Specific Aim 1). The “Build a Network” 
function was used, by entering the significantly different proteins (seed nodes) 
based on our data. Then, a network was built and analyzed an algorithm for 
up to 50 nodes. This yielded 30 networks, which were ranked in order of Z-
score. The Z-score ranks the subnetworks according to the saturation of the 
objects from the original list of seed nodes. The formula to calculate this is as 
follows: , where N is the total number of nodes in the 
database, R is the number of network objects corresponding to significant 
genes (i.e. cytokines, chemokines and surface markers entered), n is the 
number of nodes in each small network generated from the output list, and r is 
the number of nodes with data in each small network from the output list. 
The results from this analysis are summarized in Table 7. The analysis 
demonstrates that the highest ranking network generated is in fact “NFκB”, 
the signaling pathway that has been the focus of this thesis. This yielded a p-




network achieved highest scores in terms of low p-value, high Z-score and 
high G-score (the G-score is a modified Z-score based on how patterns relate 
to Canonical Pathways in the database). Processes that this network were 
associated with, based on the significant targets entered, included “positive 
regulation of the immune system”, “cellular response to LPS”, “cellular 
response to a molecule of bacterial origin”, “positive regulation of leukocyte 
migration” and “leukocyte chemotaxis”.  
The extent of the role of NFκB in how it relates to defective protein synthesis 
is shown in Figure 47A. Each arrow (connection) is based on peer reviewed 
literature evidence for a relationship between two targets, therefore, defective 
inflammatory NFκB activation observed in the impaired monocyte could 
explain differences in the linked cytokines and chemokines, but also low HLA-
DR expression in the impaired monocyte relative to the naive.   
Interestingly, the third and fourth most correlated networks were RelA (the 
gene name for p65, the important active subunit of NFκB, and the NFκB 
heterodimer p50/p65), respectively. These are all overlapping networks and 
signify the importance of defective function of NFκB in the impaired monocyte.  
A further discussion point is the highly scoring network of AP-1 (also known 
as Activator Protein-1).  AP-1 is a transcription factor which regulates the 
gene expression of various proteins relating to differentiation, proliferation and 
apoptosis. It is a heterodimer composed of proteins such as c-Fos, c-Jun and 
ATF families. C-Jun is also the fifth most commonly involved network. In 
Figure 48, it is clear that this transcription factor is activated by p38, ERK and 




involved in the monocyte inflammatory response. This cross-talk between 
pathways implies that both NFκB and AP-1 (p38, ERK and JNK) have 
overlapping roles in mounting a response to an infective stimulus. This again 
highlights the redundancy of the innate immune response. We have shown 
that indeed IκK and NFκB are suppressed, and could account for the network 
of suppressed protein responses seen. However, given that these alternative 
pathways culminating in AP-1 have not “compensated” for the decreases in 
NFκB activation, this implies that these pathways are also similarly 
suppressed.  
A further conclusion from this pathway analysis is a potential explanation for 
the pattern of MCP-1 levels (also known as CCL2) observed. This important 
chemokine is regulated by both NFκB (As per Figure 47A), but also by AP-1 
(Figure 48). Given that MCP-1 was not suppressed by an IκK-16 (a blocker of 
IκK and subsequently NFκB) in the naïve monocyte, this suggests that MCP-1 
production is an AP-1 mediated mechanism (presumably through MAPK p38, 
ERK or JNK) in the context of monocyte impairment.  
We also used the network analysis to consider some other anomalies seen in 
our data. Firstly, we found that the impaired monocyte actually produced 
consistently higher levels of IFN-α2 compared with the naïve monocyte. This 
is in contrast to Shi et al, who found that IFN-α2 was decreased during 
monocyte impairment, and replenishing IFN-α2 levels with an exogenous 
source could abrogate this impairment 128. 
Regulation of IFN-α2 production is governed by various mechanisms, 




TBK1/IκK-ε) through either interferon regulatory factor (IRF)-3 or IRF-7. 
Therefore, given that IP-10 is also suppressed in the impaired monocyte but 
IFN-α2 is elevated, this suggests that opposing effects of IRF function with 
suppressed IRF-3 and elevated IRF-7 function may be occurring (Figure 48).  
Through pathway analysis using MetaCoreTM, the two most consistent 
pathways governing HLA-DR expression were NFκB and JAK-STAT1 
signaling. The former is demonstrated in Figure 47A, and the latter is shown 
in Figure 47B. In the impaired monocyte, HLA-DR expression is decreased, 
which could be explained by deficiencies in either of these pathways. 
However, when naïve cells were treated with IκK-16, which we know inhibits 
IκK and NFκB functions, HLA-DR expression is unaffected. This suggests an 
alternative pathway is being suppressed to cause the deficient HLA-DR 
expression, and the literature and database pathway analysis is suggestive 
that the JAK-STAT1 pathway is also suppressed in the impaired monocyte. 
This is very likely as SOCS-1 (suppressor of cytokine signalling-1) is elevated 
in impaired monocyte models, and is known to inhibit JAK-STAT1 signaling. In 
fact, SOCS-1 is required for endotoxin tolerance.  
In summary, pathway analysis reveals that the most consistent signaling 
network corresponding to the data generated from our experiments is NFκB, 
which accounts for almost all of the functional changes seen in the impaired 
monocyte. Indeed, we have confirmed that the impaired monocyte does have 
suppressed IκK and NFκB functionality. Our analysis has also revealed that 
the pattern of change could also be explained by AP-1, particularly the pattern 
of MCP-1 production, thus defects in MAPK p38/ERK/JNK signaling could 




the most likely cause for decreased HLA-DR expression out with NFκB 








 Table 7. Top 5 networks involved in monocyte impairment based on pathway 








Pathways p-Value zScore gScore 
1 NF-kB positive regulation of immune system process 
(100.0%), cellular response to lipopolysaccharide 
(75.0%), cellular response to molecule of bacterial 
origin (75.0%), positive regulation of leukocyte 
migration (66.7%), leukocyte chemotaxis (66.7%) 
12 11 0 7.78e-46 323.72 323.72 
2 AP-1 positive regulation of leukocyte migration (72.7%), 
leukocyte chemotaxis (72.7%), leukocyte 
migration (81.8%), regulation of leukocyte 
migration (72.7%), positive regulation of 
intracellular signal transduction (100.0%) 
11 10 0 1.98e-41 307.38 307.38 
3 RelA (p65 
NF-kB 
subunit) 
cellular response to lipopolysaccharide (81.8%), 
cellular response to molecule of bacterial origin 
(81.8%), positive regulation of leukocyte migration 
(72.7%), cellular response to biotic stimulus 
(81.8%), leukocyte chemotaxis (72.7%) 
11 10 0 1.98e-41 307.38 307.38 
4 NF-kB 
p50/p65 
cellular response to lipopolysaccharide (81.8%), 
cellular response to molecule of bacterial origin 
(81.8%), positive regulation of leukocyte migration 
(72.7%), cellular response to biotic stimulus 
(81.8%), leukocyte chemotaxis (72.7%) 
11 10 0 1.98e-41 307.38 307.38 
5 c-Jun positive regulation of ERK1 and ERK2 cascade 
(80.0%), positive regulation of leukocyte migration 
(70.0%), regulation of ERK1 and ERK2 cascade 
(80.0%), leukocyte chemotaxis (70.0%), leukocyte 
migration (80.0%) 











 Legend to Figure 47.  
 
Pathway analysis of the impaired monocyte. The most significantly affected 
signaling network, and indeed the network with the highest Z-score was NFκB  
This network, based on the differentially expressed cytokine/chemokine and 
surface protein levels in the impaired monocyte, is demonstrated in Figure A. 
Experimental evidence from the peer-reviewed literature and network analysis 
demonstrates a proven causal link between the function of NFκB and each 
downstream protein. The regulation of HLA-DR expression is primarily 
governed by the class II transactivator (CIITA). Figure B demonstrates the 
important role of the JAK-STAT pathway in promoting HLA-DR expression. 
Decreased HLA-DR in the impaired monocyte, which does not appear to be 
due to IκK/NFκB mediated suppression, but more likely decreases in the 
function of JAK-STAT pathway.  
Source for A: MetaCoreTM, Thomson-Reuters (from entering own data).  









































ENHANCING IMPAIRED HOST DEFENCE MECHANISMS: AN 
IMMUNOLOGICAL BASIS FOR ADJUVANT THERAPIES*2 
INTRODUCTION 
 
Surgical infection continues to plague the surgeon and the patient. Despite 
various strategies to address this problem, surgical site infection (SSI) still 
occurs in up to 17 per cent of patients, with post-operative infection of some 
kind affecting 23 – 49 per cent of patients in high-risk groups.10 In particular, 
major elective surgery acts as a significant physiological insult to some of our 
patients.  
Host defense impairment, and in particular, impairment of monocyte function, 
is generally accepted as being predictive of nosocomial or secondary infection 
after surgical trauma.4   
Immunomodulatory agents have been studied clinically for many years, 
particularly in the context of trauma and sepsis without definitive outcomes.87 
Some therapies appear to show promise by improving survival in murine 
models of sepsis, such as cecal ligation and puncture. However, these mice 
or rat models carry serious limitations: subjects are genetically homogenous 
and various clinical factors observed in humans are not taken into account.9 
When these therapies are translated to humans, repeatedly the benefits in 
                                                          
2





mortality are not consistently observed. In clinical practice, the majority of 
patients will have relatively normal monocyte function and do not stand to 
benefit from adjunctive therapy. A better understanding of how those with 
impaired monocyte function will respond could allow for better translation to 
the patient. The issue of monocyte impairment itself is hugely variable among 
patients and often unpredictable, but approximately one in six trauma patients 
have subnormal monocyte function. Thus, we have adopted an approach of 
studying human monocytes ex-vivo. Low-dose stimulation of cells by LPS (10 
ng/mL) recreates not just the initial pro-inflammatory response observed 
clinically but also results in subsequent suppressed monocyte responsiveness 
to LPS exposure. The use of different healthy volunteers introduces variation 
from person to person, but permits the resulting impairment seen in some 
patients in a reproducible fashion.7,8 
In this study, we have examined the underlying immunological basis for 
established and new adjuvant therapies using an ex-vivo model of impaired 
human monocytes to determine their influence on key host defence 
mechanisms. The immunomodulatory therapies we have focused on are 






Techniques for monocyte isolation and cytokine analysis are detailed in 
the main Methods section (page 61).  
Flow cytometry 
Monocyte samples (100 μL, 100,000 cells) were stained with fluorescein 
isothiocyanate-labeled anti-human CD14, phycoerythrin-labeled anti-HLA-DR 
antibodies (BD Biosciences, La Jolla, CA) and separately phycoerythrin-
labeled anti-PD-L1 (BD Biosciences, La Jolla, CA) to measure monocyte 
surface expression of these proteins. Manufacturer instructions were closely 
followed. Monocytes were pelleted by centrifugation, washed with Dulbecco 
Phosphate Buffered Saline (Sigma Aldrich, St. Louis, MO), and fixed in 300 
μL of 1 per cent paraformaldehyde solution.  
At the indicated time points, monocyte surface levels of CD14, HLA-DR 
and PD-L1 expression were analysed using a FACS Calibur flow cytometer 
(Becton Dickinson, San Diego, CA). A total of 5,000 gated events were 
acquired. Mean fluorescence intensity (MFI) for each surface marker was 
analysed on monocytes  using Cell Quest software (Becton Dickinson, San 
Diego, CA).   
Adjuvant therapies 
Human recombinant IFN-γ, GM-CSF and IκK-16 were purchased from Sigma 
Aldrich, St. Louis (MO). Compounds were reconstituted from stock solution as 
per manufacturer’s instructions and diluted in media to the appropriate 




100 ng/mL rGM-CSF and 50 nM IκK-16 as determined by dose-response 
experiments (data not shown). Adjuvants rIFN-γ and rGM-CSF were then 
added to cell culture 1 h after isolation, simultaneously with 10 ng/mL LPS for 
a duration of 16 h (until 17 h post-isolation). IκK-16 was given at time zero for 
1 h, cells were washed with PBS and re-suspended in fresh media then 10 
ng/mL LPS was added to cell culture. No further doses of immunoadjuvants 
were given at or after the 100 ng/mL LPS challenge at 17 h.  
Statistical Analysis  
Each donor was used as its own control. Wilcoxon-signed ranked test was 
used for calculation of significant differences where appropriate. Naïve 
conditions (no LPS 10ng/mL pre-treatment) and then each immunoadjuvant 
therapy were compared to the impaired monocyte. Significance was set at P < 
0.05. Preliminary experiments were used to estimate that a sample size of 7 
was required to obtain a power of 0.8 (80%).  SigmaPlot was used for 













Timeline of the experimental protocol. Following monocyte isolation from 
healthy volunteers, following 1 hour of rest, cells are cultured either in media 
only (naïve) or with low dose 10 ng/mL LPS for 16 hours. Monocytes are then 
re-suspended in fresh media and challenged with high dose 100 ng/mL LPS 
to assess the inflammatory response. Adjuvant strategies aim to modulate the 







Low-dose 10 ng/mL LPS stimulated ex-vivo human monocytes in culture to 
produce higher levels of TNF-α at 17 h compared with its naïve control 
(Figure 50). However, when these cells met a subsequent larger LPS 
challenge of 100 ng/mL, they exhibited decreased levels of TNF-α when 
compared to the naïve cells, most noticeably at 21 h. Monocytes impaired by 
low-dose LPS exposure also exhibited a decreased ability to produce IL-10, 
an anti-inflammatory cytokine, following the LPS challenge. This decrease in 
IL-10 levels was sustained, reaching statistical significance at 21, 29 and 41 h 
after the LPS challenge as seen in Figure 51. Monocyte surface HLA-DR 
expression, a parameter reflecting antigen-presenting capacity measured by 
flow cytometry, was modestly but consistently decreased in the LPS 10ng/mL 
exposed monocyte at 17 h (Figure 52). CD14 and PD-L1 expression was 
similar between naïve and impaired conditions.  
 
IFN-γ treatment 
Recombinant IFN-γ treatment increased the capacity for the monocyte to 
produce TNF-α. In response to the initial 10 ng/mL LPS, TNF-α levels 
increased in the impaired monocyte. Subsequent to 100 ng/mL LPS challenge 
at 17 h, levels of TNF-α production were higher in IFN-γ treated monocytes at 
21 and 29 h. IL-10 levels appeared to initially decrease in IFN-γ treated 




to the impaired monocyte, HLA-DR expression was consistently sustained in 
response to IFN-γ treatment at 21, 29 and 41 h. Monocyte CD14 expression 
was decreased as a consequence of IFN-γ treatment, most noticeably at 41 h 
(Figure 53). IFN-γ treated monocytes had markedly increased PD-L1 
expression at every time point (Figure 54).  
GM-CSF treatment 
GM-CSF appeared to decrease TNF-α and increase IL-10 at 17 h, and then at 
all subsequent time points following 100 ng/mL LPS. However, these 
differences never reached statistical significance. GM-CSF did not have any 
significant influence on monocyte HLA-DR, CD14 or PD-L1 expression.  
IκK-16 treatment 
Despite the short exposure to IκK-16, there was a consistent and sustained 
decrease in TNF-α production when compared to the impaired monocyte, 
most noticeable at 17 h and 41 h. Despite a decrease in TNF-α, there was no 
decrease in IL-10 levels. In fact, monocytes treated with IκK-16 trended 
towards an increased capacity to produce IL-10 following an LPS challenge 
when compared with the impaired monocyte.  IκK-16 also did not increase 
monocyte HLA-DR or PD-L1 expression; however, CD14 expression was 

































C. Impaired without and with GM-CSF 
Impaired
GM-CSF
Figure 50. Effect of immunoadjuvants on TNF-α production in the impaired 
monocyte. 
           
           
           







Monocytes were cultured in naïve (media only) or impaired (10ng/mL) 
conditions, with or without the three adjuvant regimes. Cells were then given 
the 100 ng/mL LPS challenge. Supernatant TNF-α protein was measured by 









































































































































































































D. Impaired without and with IκK-16 
Impaired
IκK-16 

















Monocytes were cultured in naïve (media only) or impaired (10ng/mL) 
conditions, with or without the three adjuvant regimes. Cells were then given 
the 100 ng/mL LPS challenge. Supernatant IL-10 protein was measured by 
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Monocytes were cultured in naïve (media only) or impaired (10ng/mL) 
conditions, with or without the three adjuvant regimes. Cells were then given 
the 100 ng/mL LPS challenge. Surface HLA-DR expression was measured by 
FACS. Mean ± S.E.M. N = 7. *p  < 0.050. 
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Monocytes were cultured in naïve (media only) or impaired (10ng/mL) 
conditions, with or without the three adjuvant regimes. Cells were then given 
the 100 ng/mL LPS challenge. Surface CD14 expression was measured by 
FACS. Mean ± S.E.M. N = 7. *p  < 0.050. 
 






































































































































































































D. Impaired without and with IκK-16 
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E. Effect of IFN-γ (gray) on PD-L1 
Expression in the Impaired Monocyte 













Legend for Figure 54.  
 
Monocytes were cultured in naïve (media only) or impaired (10ng/mL) 
conditions, with or without the three adjuvant regimens. Cells were then given 
the 100 ng/mL LPS challenge. Surface PD-L1 expression was measured by 
FACS. Mean ± S.E.M. N = 7. *p  < 0.050.Figure E demonstrates a 
representative histogram showing the increase in PD-L1 expression in 
















Monocytes were cultured on conditions of either naïve (media only), impaired 
(low dose 10 ng/mL LPS), or impaired with adjuvant as previously described 
for 16 hours, after an initial hour of rest. At 17 hours, cells were stained with 
Trypan blue and were counted by standard microscopy to determine cell 
viability between conditions. N.S., not statistically significant between groups 
(Repeated Measures ANOVA).   























N = 7 
N.S. 





The purpose of this study was to understand how potential immunoadjuvant 
therapies influence host defense mechanisms in a human ex-vivo model of 
monocyte impairment. Firstly, our data demonstrate that the initial response to 
endotoxin is a pro-inflammatory phenotype, but then impaired cytokine 
production occurs in response to a further endotoxin challenge. These 
findings are in agreement with many in-vitro and ex-vivo models in the 
literature.5,46 Furthermore, this model is representative of both human 
endotoxemia models and clinical studies examining the immune response 
after major elective surgery, trauma and sepsis. 86 Specifically, the blunted 
capacity of monocytes to express HLA-DR and to produce TNF-α has 
repeatedly been shown to predict secondary infection and often death. This 
has formed the basis for numerous randomized clinical trials designed to 
enhance the monocyte inflammatory response.3,84 
IFN-γ has been shown to act through the IFN-γ receptor and 
subsequently via the JAK-STAT1 pathway to activate monocytes and 
macrophages. Our results show that IFN-γ restores the capacity of the 
monocyte to produce TNF-α and augment HLA-DR expression. These 
findings are in keeping with previous in-vitro studies.47 In addition, these 
positive effects by IFN-γ have been shown in-vivo with numerous clinical 
studies.91 
We have shown that IFN-γ also increases the expression of PD-L1 on 
the surface of monocytes. Recent studies to understand the signaling and role 




activation of the JAK-STAT1 pathway, also leads to higher PD-L1 expression 
in natural killer cells.130 We believe this likely represents a negative feedback 
mechanism to suppress endogenous IFN-γ by T-cells in the context of highly 
abundant exogenous sources. Future research is required to determine if PD-
L1 will be as clinically applicable as a marker or therapeutic target in the field 
of surgical infection as it has been in oncology.  
Our data has not demonstrated any significant modulatory effect of 
GM-CSF on the impaired monocyte. Preliminary dose-determining studies 
suggested that IL-10 production was augmented in the naïve monocyte; 
however, this effect may be attenuated in the setting of monocyte impairment.   
Surgical trials using GM-CSF have shown increased peri-operative HLA-DR 
expression, and our results suggest that this effect may be through promotion 
of myelopoeisis to produce new, functioning monocytes rather than 
modulating existing circulating impaired monocytes. 93 
IκK-16 is a small molecule inhibitor of IκK, acting to suppress this pro-
inflammatory signaling pathway. “Glue Grant” studies of the genomic 
response in surgical patients following trauma demonstrated that the 
magnitude of both the pro- and anti-inflammatory response determined patient 
outcome.1 Due to the presumed risks of persistent suppression of 
inflammation, a short exposure of this therapy was used. Our results show 
that, despite short exposure, decreases in TNF-α production are sustained. 
Interestingly, levels of the anti-inflammatory cytokine IL-10 were restored 
towards the level of the naïve monocyte. While the use of IκK-16 have 
improved end organ function in pre-clinical models of hemorrhagic shock and 




increase the risk of nosocomial infection in some patients.77 One unexpected 
finding of the effect of IκK-16 was the augmentation of CD14 expression, 
especially in the later stages after stimulation. CD14 acts as a receptor for 
LPS, binding to TLR4 homodimers for signal transduction in the monocyte. 
Studies in trauma patients have shown that the detachment of this receptor 
following excessive stimulation, examined either by decreased monocyte 
expression or increased soluble CD14, is a predictor of infection and 
death.131,132 We believe that by decreasing the early and late responses to 
LPS by limiting IκK activation, this might represent a mechanism to preserve 
the capacity to respond to future exposure to pathogens and may warrant 
further study.   
This study does have some limitations. Due to the ex-vivo and 
artefactual nature of this study, we cannot account for how other immune cells 
might respond to these immunomodulatory agents. Furthermore, the 
leukocyte response to LPS shares 88% of the same genomic response to 
trauma, as demonstrated in high throughput Glue Grant studies.1 
In conclusion, IFN-γ is the most effective immunoadjuvant in terms of 
increased TNF-α production and HLA-DR expression, which are two important 
predictors of surgical infection. However, by modulating a different signaling 
pathway, IκK-16 restored IL-10 production and augmented CD14 expression. 
Correcting impaired host defenses is a key factor in preventing and surviving 
surgical infection. We, as surgeons, are still trying to modulate pathologic 
immune responses to improve rates of surgical infection and death in our 
patients. Careful clinical judgment in terms of patient selection and timing is 





MONOCYTE FUNCTION IN THE INFECTED SURGICAL PATIENT  
INTRODUCTION 
 
 Surgical patients are at risk from numerous different forms of 
nosocomial infection during their hospital course. They may present with an 
acute intra-abdominal infection such as diverticulitis, or from a contaminated 
wound following trauma. The critically unwell patient often has invasive lines 
which can act as a foreign body, and can be ventilated which carries a risk of 
pneumonia. Finally, surgical site infection (SSI) is of political importance as a 
potential measure of quality of care, and can range from superficial wound 
infection to deep organ or cavity space infection. Patients with SSI’s often 
require additional interventions, have a longer hospital stay and experience 
greater morbidity. Previously in this dissertation, impaired host defense was 
highlighted as a risk factor in the probability of surgical site infection, often 
measured by low monocyte HLA-DR or low ex-vivo TNF-α production in 
response to a stimulus. Few studies have examined the immune response in 
surgical patients after the so called clinical “second hit” of infection.  
In this chapter, surgical patients from a University Colon and Rectal 
Surgery practice who were diagnosed with infection were studied. Patients 
were selected based on being “in homeostasis with or tolerant of” their 
infective source i.e. likely to bear the clinical phenotype of in-vivo monocyte 




where patients had a systemic inflammatory response with or without shock 
and multi-organ failure. 
The aims of this study was 1) to determine monocyte function in major 
surgical patients with infection, as judged by HLA-DR expression and ex-vivo 
cytokine production and 2) investigate the expression of intracellular negative 
regulator molecules that could represent a potential marker or indeed driver of 
suppressed monocyte function.  
METHODS 
Following IRB approval and written informed consent, peripheral blood 
was obtained by phlebotomy. Blood samples were taken both during 
episodes of infection and after clinical recovery (median 60 days after 1st 
sample). As a comparator group, peripheral blood was also obtained from 
healthy volunteers. 
The majority of patients were hemodynamically stable and most were 
diagnosed with deep surgical site infection, as defined by an abscess in an 
organ or cavity space. The specific sources of infection included intra-
abdominal abscess (n=12), pneumonia (n=2), perineal abscess (n=1) and line 
sepsis (n=1). Patients were aged 25-81 years, 6:10 (M:F). Healthy volunteers 
were aged 19-32 years, 7:3 (M:F).  
Peripheral blood was obtained using EDTA tubes, which prevented 
clotting and allowed ex-vivo testing of the immune response. Monocyte HLA-
DR expression (FACS) and cytokine levels (ELISA) were examined at 




stimulation (100 ng/mL) for 4h (Fig. 56). Plasma samples were obtained after 
centrifugation of whole blood, and stored at -80°C until later testing. Standard 
individual ELISA assays were performed for TNF-α, IL-10 and IL-6 (as 
described the main Methods section, from page 61). Flow cytometry was 
performed on whole blood using the protocol described in the main Methods 
section, from page 61. The main difference in protocol was that whole blood 
was lysed with hypotonic lysis buffer to exclude RBCs from analysis. For the 
gating strategy, the monocyte population was selected based on forward and 
side scatter properties, and confirmed by gating only on CD14 positive cells . 
Monocyte HLA-DR is expressed as mean fluorescence intensity (MFI). The 
same antibodies for CD14 (FITC) and HLA-DR (PE) were used as described 
in the main Methods section (from page 61), however, samples were run 
using a BD LSRII flow cytometer (BD Biosciences, CA).  
The remaining monocytes were isolated by magnetic bead positive 
selection and mRNA was extracted  and analyzed via qRT-PCR, to compare 
the ratio of normalized mRNA expression (using 18S) between the patient and 
healthy control samples (as described in the main Methods section, from 
page 61). For statistical analysis, Mann-Whitney-U tests and Unpaired T-tests 












Peripheral blood was taken from surgical patients with infection. Monocyte 
function was determined by CD14 positive monocyte HLA-DR expression by 
FACS, and ex-vivo LPS stimulation in whole blood for 4 hours. At 4 hours, 
HLA-DR expression was measured again to determine the response, as well 
as concentrations of plasma cytokines TNF-α, IL-10 and IL-6 by ELISA. In 
addition, monocytes were isolated from patient samples using CD14 magnetic 
bead isolation, and monocyte RNA was extracted and qRT-PCR was used to 
determine the expression of various known negative regulators of monocyte 
function. Further samples were taken from patients later in their course of 
illness, presumably moving toward health after hospital discharge; healthy 





Monocyte HLA-DR expression 
Patients had statistically significant lower baseline HLA-DR expression (0h, 
unstimulated) compared to healthy volunteers (Figure 57). Following LPS 
stimulation, healthy volunteers upregulated HLA-DR expression to MFI of 
approximately 15,000  compared with only 8,000 in patients during their initial 
sample (p<0.05). Levels of HLA-DR either prior to or after LPS stimulation did 
not seem to improve in follow-up samples compared with initial patient 
samples.   
Cytokine production 
Circulating levels of TNF-α were virtually undetectable in healthy volunteers 
and patients (Figure 58). The levels of TNF-α appear slightly higher in 
patients, however, these were below the lower limits of detection in the assay 
and did not reach statistical significance. Decreased monocyte TNF-α 
production was observed in patients in response to LPS stimulation, 
compared with healthy volunteers. Follow-up samples from patients also had 
lower levels of TNF-α production compared with health volunteers but also 
appeared lower than initial patient samples. 
Circulating levels of IL-10 were increased in patients compared to the 
healthy controls (Figure 59, p<0.05). Levels of IL-10 did decrease in the 
follow-up patient samples. After 4 hours of LPS stimulation, there were 




of LPS stimulation remained higher in patients compared with healthy 
volunteers. 
Circulating plasma IL-6 levels (prior to stimulation) were elevated in the 
initial patient samples compared to healthy volunteers, in which IL-6 levels 
were below the lower limits of detection (Figure 60). Following 4 hours of ex-
vivo LPS stimulation, this pattern was reversed. Healthy volunteers increased 
their IL-6 levels to approximately 2,000 pg/mL, compared with a mean IL-6 
level of less than 1,000 pg/mL in patients with infection. Follow-up samples for 
IL-6 were not available for analysis at the time of writing. 
Gene expression of negative regulators of the inflammatory response 
Based on a thorough literature search, the expression of the following 
negative regulator molecules were analysed; ATF3, IRAK-M, TNFAIP3 (A20), 
SOCS-1, SOCS-3 and SHP-1. These were compared to 18S as the 
housekeeping gene for normalization. Gene expression of IRAK-M, a known 
negative regulator of inflammation, was consistently upregulated in patients 
with infection as compared to healthy controls (p<0.05) (Figure 61). Data for 
the other negative regulators were not significantly different (data not shown).  
Interestingly, IRAK-M mRNA expression appeared to decrease after clinical 




























Monocyte HLA-DR expression was determined in both unstimulated blood 
(baseline 0 h) and after 100 ng/mL LPS stimulation ex-vivo for 4 hours. HLA-
DR expression using PE-tagged antibodies was determined on CD14 positive 






































































































TNF-α concentration was determined in both unstimulated blood (baseline 0 h 
and after 100 ng/mL LPS stimulation ex-vivo for 4 hours by ELISA. * p < 0.05, 












































































IL-10 concentration was determined in both unstimulated blood (baseline, 0 h) 
and after 100 ng/mL LPS stimulation ex-vivo for 4 hours by ELISA. * p < 0.05, 
Mann-Whitney U test. # p = 0.057. 




























































































IL-6 concentration was determined in both unstimulated blood (baseline, 0 h) 
and after 100 ng/mL LPS stimulation ex-vivo for 4 hours by ELISA. * p < 0.05, 
Mann-Whitney U test. 













































Monocyte IRAK-M expression was determined by qRT-PCR with data 
normalized to 18S. For fold changes, patient samples were compared to 



































A proportion of surgical patients have a suppressed inflammatory response 
which impairs their ability to clear infection. This can result in the permissive 
escape of microbes from the chest, urine or wounds into the bloodstream, 
leading to bacteremia. As a result, multi-organ failure and death is a 
consequence in some patients. Prolonged or repeated physiological insults 
through repeated operations, infection or trauma, and certain therapies can 
lead to suppressed monocyte function. Such patients with “deactivated” host 
defenses or “immunoparalysis” can tolerate infective sources, such as 
abscesses, to persist without clearance. It was this clinical phenotype of 
surgical patient that was selected for study in this chapter.  
 Firstly, we aimed to determine monocyte function within these patients. 
Identification of such patients at higher risk for failure to clear infection is of 
clinical interest. Furthermore, such a patient may benefit from a therapy that 
could “reactivate” monocyte function. Much of the principle underpinning the 
isolated monocyte model of impairment design in Specific Aim 1 held the 
assumption that these patients had decreased ability to produce TNF-α in 
response to LPS as well as decreased levels of HLA-DR expression. These 
results confirm that the patients studied with surgical infection did have 
suppressed monocyte function, compared to healthy volunteers. Not only was 
monocyte HLA-DR expression decreased prior to stimulation, but the patient’s 
monocytes were unable to upregulate HLA-DR expression in response to LPS 
stimulation. These findings are in keeping with prior studies in sepsis and 




also the capacity to produce IL-6 was decreased. These data confirm the 
validity of the impaired monocyte model.  
 Interestingly, circulating plasma levels of IL-6 and also IL-10 prior to 
stimulation were elevated in patients compared with healthy controls. This is 
in keeping with results from other groups 27,133. Mechanistically, this could in 
part explain the decreased monocyte responsiveness. IL-10 is known to 
decrease TNF-α gene expression and downregulate HLA-DR expression. IL-
10 has previously been discussed as a potential target to block and prevent 
this loop of monocyte impairment 134. 
 A difference between the impaired monocyte model and the patient 
observations is the increased IL-10 levels observed in infected patients. In our 
model, the impaired monocyte consistently suppresses IL-10 production. 
There are various explanations for this. Firstly, these samples were taken 
from whole blood rather than a single cell suspension of monocytes. Other 
documented sources of IL-10 in sick surgical patients include neutrophils and 
T-cells that are polarized towards a Th2 phenotype, which would explain this 
difference 135,136. Timing is a critical consideration. Our results indicate that 
monocytes in culture increase IL-10 levels over time in regardless of 
conditions. At 17 hours, fresh media is used to determine the responsiveness, 
which is obviously not the case with the whole blood 100 ng/mL LPS 
challenge. This could mask the increased IL-10 levels.    
 There are numerous limitations to this study. This thesis demonstrates 
a high degree of variability in monocyte function from person to person in 




between these patients. There is variability in the source and severity of 
infection, in co-morbidity and treatments and critically, there were no specific 
criteria of sampling times relative to the diagnosis of infection, rather these 
patients were studied as targets of opportunity. This study was a spontaneous 
experiment of surgical practice. Both initial and follow-up samples are likely to 
be at different times within the clinical course from patient to patient, including 
a few who appeared to have fully recovered. Other limitations include 
potential selection bias with respect to patients, differences in age between 
patients and healthy volunteers, and attrition bias in that every immune 
parameter could not be measured in every patient. This is partly due to small 
volumes of blood available for analysis.   
 Nevertheless, the patients at the time of infection had elevated levels of 
IRAK-M expression relative to healthy volunteers, and this elevation appeared 
to return towards the level of healthy volunteers after clinical recovery. These 
data are similar to other groups studying patients with sepsis 137,138. IRAK-M is 
likely to be involved in a negative feedback loop, induced by stimuli such as 
LPS, which in turn suppress the assembly of IRAK 1/4 and decrease TRAF-6, 
therefore suppressing the inflammatory response through IκK and NFκB 
inhibition (Figure 62). In fact, various groups in experimental models have 
shown that silencing or knockout of IRAK-M results in an abrogation of 
impairment with increased cytokine production 139. 






Figure 62. Proposed mechanism of IRAK-M mediated suppression of 

















Monocytes in surgical patients will likely have initial stimulation such as from 
an operation, infection or soiling of the peritoneal cavity resulting in the 
stimulation of inflammatory pathways such as IκK, and resulting upregulation 
of IRAK-M. This negative regulator is known to suppress TLR signaling, 
resulting in a suppressed inflammatory response. 
  
Pro-inflammatory response 










In summary, this small observational study demonstrates that patients with 
surgical infection have impaired monocyte function, as judged by decreased 
TNF-α production in response to ex-vivo LPS stimulation and decreased HLA-
DR expression. These results confirm to some extent the in-vitro impaired 
monocyte model. Upregulation of IRAK-M in infected patients may provide a 
potential mechanism of suppressed IκK activation and impaired responses 






CONCLUSIONS AND OVERVIEW 
 
Impaired monocyte function is a central component to an immune 
suppression of host defense mechanisms following major trauma, surgery or 
infection. Although this occurs in only a subset of patients, this is predictive of 
poor outcomes and remains an attractive therapeutic target.  
 This model of isolated monocytes from healthy volunteers allows for a 
pure population of reproducibly impaired monocytes to be studied for 
underlying mechanisms and potential therapy. This is characterized by a 
reduced capacity to produce many cytokines and chemokines (such as TNF-α 
and IL-10), and reduced HLA-DR expression, as a result of low dose LPS 
exposure. This constellation of defects is representative of the patient with 
impaired host defenses.  
 The focus of this thesis has been to understand the effects of such 
impairment on NFκB and IκK signaling. While other pathways may also be 
involved, NFκB which is an important pro-inflammatory signaling pathway is 
indeed altered in its function in the context of monocyte impairment. Our 
results reflect decreased p65 protein, diminished p65 phosphorylation and 
decreased IκB degradation in response to a subsequent challenge, 
demonstrating suppressed NFκB activation in the impaired monocyte. The 




suppressed IκK phosphorylation. This is seen most evidently within 30 
minutes after the LPS challenge. This suppression of IκK activation 
corresponds with the decreased TNF-α and IL-10 production as a result of 
impairment. This defect is likely to be a result of a negative feedback loop that 
is limiting upstream signaling pathways, where we found downregulated gene 
expression of TRAF-6. TRAF-6 is considered the gatekeeper of toll-like 
receptor signaling, and its suppression in the impaired monocyte, in part, 
explains how decreased IκK activation occurs.  
 Loss of function studies with a novel, specific IκK inhibitor 
demonstrated cause and effect relationship of the IκK pathway, by 
recapitulating the impaired monocyte as measured by decreases in TNF-α 
and IL-10 production. This occurred in a dose-dependent fashion, proving the 
hypothesis that decreased IκK activity leads to impaired monocyte function. 
Interestingly, HLA-DR expression was not influenced by IκK inhibition, and is 
likely to be governed by other altered signaling pathways. Interestingly, 
miRNA-155 appeared to increase in response to LPS, but decreased with IκK 
inhibition. This negative effect of IκK inhibition on miRNA-155 may provide an 
additional mechanism to limit early inflammation, and perhaps late 
immunosuppression, which may offer clinical benefit. Early inhibition of IκK 
may be useful in some clinical settings, such as major trauma and shock, by 
limiting an excessive cytokine and chemokine response which is also 
associated with poor outcomes, without decreasing HLA-DR expression. 
However, it is likely that profound or prolonged IκK inhibition would likely be 




 Understanding how our findings correspond with in-vivo monocyte 
impairment would be worthy of further study. One limitation of the study was 
that while single cell suspension allows focused mechanistic and signaling 
studies, the interaction of monocytes with other cells and organs in an in-vivo 
system, such as in an animal model, could not be elucidated. However, during 
the time of this thesis, we did study monocyte function in surgical patients with 
infection. We found that they had decreased TNF-α and HLA-DR expression, 
which confirms the validity and clinical relevance of the in-vitro model. Further 
observations in animal models or humans following trauma to examine IκK 
function and downstream cytokine networks could better inform and translate 
these findings at a systemic physiological level. This may also aid the 
understanding of negative feedback loops involved in upstream signaling 
dynamics, and how adjuvants like IκK-16 and IFN-γ modulate the monocyte 
















Legend to Figure 63.  
 
 
We hypothesized that monocyte impairment occurred as a result of feedback 
inhibition of IκK. First, we developed a model of decreased monocyte function, 
as judged by decreased TNF-α and decreased IL-10 in response to an LPS 
challenge. Impaired monocytes also had decreased HLA-DR 
expression.*Decreased IL-10 production in the impaired monocyte was 
contrary to the hypothesis. In impaired cells previously exposed to low dose 
10 ng/mL LPS, decreased IκK phosphorylation was observed. Manipulation of 
this pathway with  an IκK inhibitor resulted in decreased TNF-α and IL-10 
production, as seen in the impaired monocyte. HLA-DR was not decreased by 
IκK inhibition. Therefore, we conclude that decreased cytokine production of 
the impaired monocyte occurs as a result inhibition of IκK, although 
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scenarios in combination with clinical data of fluid prescription in surgical patients. Resulted in 
regular fluid teaching program, with re-audit complete. 
 
 Audit of Compliance with VTE Prophylaxis including Reassessment in WIH 
Western Isles Hospital, Stornoway, Isle of Lewis, 2012. 
Conceptualised, designed, collected data for & presented at a local meeting. Resulted in a change 
of practice, with new documentation and the second cycle is about to begin.  
 
 Audit of Surgical Management of Abscesses in the Colorectal Unit.  
Western General Hospital, Dec 2013.  
Audit of time/inpatient stay from admission to drainage, and whether this was undertaken “out 
of hours”, presented to the regional Colorectal Morbidity & Mortality meeting. 
 
 Audit of Risk assessment & Appropriate Heparin/TED prescription in the Urology Unit, 
WGH.  
Western General Hospital, Edinburgh, 2014  
I supervised an FY1 doctor in the design, collection and data analysis. We presented the first 
cycle, with a view to implementing an intervention through stickers and for re-audit.  
 
 Loop ileostomy patient education in an American Colorectal Unit.  
University Hospital, Louisville, Kentucky, 2016.  
An initial audit revealed a high rate of readmission following loop ileostomy formation due to 
dehydration and partial small bowel obstruction. An intervention of a patient orientated 
educational card was provided to all patients undergoing a new loop ileostomy formation to 
educate them on monitoring ileostomy output, do’s and don’ts of appropriate foods and what to 
do if concerns regarding ileostomy output. The current status of this project is in the progress of 







Peer Reviewed Publications 
 
Galbraith NJ, Walker SP, Carter JV, Polk HC. Past, present and future of augmentation of monocyte 
function in the surgical patient. Surgical Infections. 2016 Surg Infect (Larchmt). 2016 Oct;17(5):563-9. 
 
Carter JV, Roberts HL, Pan J, Rice JD, Burton JF, Galbraith NJ, Eichenberger MR, Jorden J, Deveaux P, 
Farmer R, Williford A, Kanaan Z, Rai SN, Galandiuk S. A Highly Predictive Model for Diagnosis of 
Colorectal Neoplasms Using Plasma MicroRNA: Improving Specificity and Sensitivity. Ann Surg. 2016 
Oct;264(4):575-84.  
 
Galbraith NJ, Walker SP, Galandiuk S, Gardner SA, Polk HC. The significance and challenges of 
monocyte impairment: for the ill patient and the surgeon. Surgical Infections. 2016 vol. 17 (3) pp 303-12. 
 
Billeter AT, Galbraith N, Walker S, Lawson C, Gardner SA, Sarojini H, Galandiuk S, Polk HC. TRPA1 
mediates the effects of hypothermia on the monocyte inflammatory response. Surgery. 2015 Sep 
30;158(3):646-54. 
 
Galbraith NJ, Cullis PS, O’Dwyer PJ. Letter to the Editor: Minimally invasive surgery for malignant 
adrenal tumors. The surgeon. 2014 Apr 30;12(115):e116-116. 
 
Parnaby CN, Galbraith N, O'Dwyer PJ. Importance of the Adrenal Gland Blood Supply During 
Laparoscopic Subtotal Adrenalectomy. J Laparoendosc Adv Surg Tech A. 2010 Mar 8 
 
Parnaby CN, Galbraith N, O'Dwyer PJ. Experience in identifying the venous drainage of the adrenal 
gland during laparoscopic adrenalectomy. Clin Anat. 2008 Oct; 21(7): 660-5. 
 
 
Papers in progress: 
 
Galbraith NJ, Walker SP, Cahill M, Bishop C, Manek S, Reid M, Polk HC. Enhancing impaired host 
defense mechanisms: An immunological basis for adjuvant therapies.  
Submitted to Journal of Leukocyte. Biology, December 2016 
 
Galbraith NJ, Carter JV, Netz U, McCafferty M, Yang D, Fry DE, Galandiuk S.  A contemporary meta-
analysis of laparoscopic lavage for perforated diverticulitis.  
Submitted to JAMA Surgery, November 2016 
 
Walker SP, Galbraith NJ, Bishop C, Reid M, Gardner SA, Polk HC. Interferon-gamma enhances 
monocyte function and increases PD-L1 expression. 
Accepted for oral presentation at ASC, 2017, Las Vegas. Target journal: PLoS One.  
 
Galbraith NJ, Walker SP, Carter JV, Gardner SA, Galandiuk S, Polk HC. The role and regulation of IκK 
in relation to impaired monocyte function. 
Accepted for presentation at ASC, 2017, Las Vegas. Target journal: Surgery 
 
Galbraith NJ, Walker SP, Gardner SA, Carter JV, Manek S, Galandiuk S, Polk HC. Surgical patients with 
infection have suppressed monocyte function and increased IRAK-M expression.  
Accepted for presentation at ASC, 2017, Las Vegas. Target journal: Journal of Immunology 
 
Galbraith NJ, Walker SP, Carter JV, Gardner SA, Galandiuk S, Smith JW, Barnes SL, Polk HC.  
Major trauma causes microRNA changes associated with pro-inflammatory cytokine signaling. Target 
journal: Annals of Surgery.  
 
Galbraith NJ, Netz U, Carter JV, Polk HC Jr., Galandiuk S. Long term outcomes in patients diagnosed 
with Indeterminate Colitis – a retrospective case review. 
 
“Radiofrequency ablation for breast cancer liver metastasis: A case of tumour progression” 





“MBL and the acute phase response: A factor in post-operative infection following liver resection” 
Galbraith NJ, Wigmore SJ. 
 
“Key Factors affecting Compensatory Renal Hypertrophy following Live Kidney Donation” 




Poster presentation, Surgical Infection Society Annual Meeting, West Palm Beach, FL. May 2016.  
“Dysregulation of NFκB in the impaired human monocyte leads to a blunted TNF-α response” 
 
Oral presentation, Academic Surgical Congress, Jacksonville, FL. February 2016 (First Author & Presenter) 
“MicroRNA dysregulation associated with function of the impaired monocyte” 
 
Price Seminar, Price Institute of Surgical Research, Department of Surgery, University of Louisville, March 
2015 
“Drug prophylaxis and other adjunctive therapies for septic complications in the surgical patient” 
 
Oral presentation, Academic Surgical Congress, Las Vegas February 2015 (First Author & Presenter) 
“TRPA1 mediates the effects of hypothermia on the monocyte inflammatory response” 
 
Oral presentation (Vascular/Transplant Section), Association of Surgeons of Great Britain & Ireland, 
Harrogate, 2014 (First Author & Presenter) 
“Factors affecting Compensatory Renal Hypertrophy following Live Kidney Donation” 
 
Poster, Association of Surgeons of Great Britain & Ireland, Harrogate, 2014 (First Author & Presenter) 
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Poster, Association of Surgeons in Training, 2014 (First Author & Presenter) 
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Poster, European Society for Coloprotology (ESCP), Vienna, 2012 (First Author) 
“Fluid prescription in Surgical Patients by Junior Doctors” 
 
Poster, European Society of Organ Transplantation (ESOT), 2011 (Third Author) 
"Compensatory Renal Hypertrophy Following Laparoscopic Live Kidney Donation: No Reduction 
Compared with Open Techniques"  
 
Poster, ASGBI International Surgical Congress, 2010 (Second Author) 
"Patient Outcome Following Laparoscopic Adrenalectomy for Adrenal Metastasis"  
 
Poster, British Association of Endocrine and Thyroid Surgeons Annual Meeting, 2009 (Presenter and First 
Author) 
“Laparoscopic adrenalectomy in metastatic renal cell carcinoma.” 
 
Oral presentation, Scottish Renal Association Meeting, 2009 (Presenter and First Author) 
“Renal function in patients following live donor nephrectomy.” 
 
Oral presentation at the Winter Meeting of the British Association of Clinical Anatomists, 2007 (Second 
Author) 
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“How to Pass the MRCS OSCE Volume 1 (Oxford Specialty Training: Revision Texts)” by Pradip K. 
Datta, Chris Bulstrode, Vasha Kaur 
Reviewed by P. Cullis & NJ. Galbraith 
Published at British Journal of Surgery (BJS) Online: Book Reviews 
 
“Fundamentals of Surgical Practice (3rd Edition) by Andrew Kingsnort and Douglas Boweley 
Reviewed by P. Cullis & NJ. Galbraith 
Published 24th Feb 2014 in Surgeons News, Royal College of Surgeons, Edinburgh  
Teaching 
 
I am registered for my third consecutive year as an eTutor for the Edinburgh Surgical Sciences 
Qualification MSc programme, teaching junior doctors in the Colorectal & Urology modules through Case 
Based Discussion enforcing basic science principles and formally assessing them (2013 – present).  
 
I have carried out teaching to medical students including bed side teaching, lectures and interactive 
tutorials.  
 
There has been ample opportunity to teach within the academic foundation programme. Recent teaching 
sessions included: 
 Surgical emergencies for the FY1 
 Topics in Gastroenterology (3rd year medical students) including inflammatory bowel disease, 
upper GI bleeds and colorectal cancer.  
 
In my recent clinical year before leaving Edinburgh, I was an examiner in the 3rd year OSCE’s for their GI 
block with the University of Edinburgh.  
 
Since my time in Louisville, I have regularly taken part as an examiner in the 3rd year medical student 
surgical oral exams, as well as regular attendance on Dr. Polk’ teaching trauma rounds.  
 
 
Management, Leadership & Teamwork 
 
Following on from heavy involvement in the audit process, following a successful presentation of our VTE 
audit in the Western Isles Hospital, I attended meetings with the Medicines Management team to establish 
new guidelines based on our audit, which was highly successful.  
 
Since then, I have organized X-Ray meetings, the Stone meeting in my current Urology rotation, and 
recently presented a paper at our departmental Journal Club in the Colorectal Surgery.  
 
As a research fellow in the Price Institute of Surgical Research, I was responsible for up to 5 students in 
the lab at any time. This involved leadership in pioneering and delegating individual projects, supervising 
experimental technique, assisting in data analysis and presentation of results. Leadership of this team 
provided a challenge in ensuring all members of the team benefited. This was a highly successful endeavor 
resulting in a medical student presenting at the Research Louisville symposium (2016) and a prospective 
medical student presenting our work at national level. This role also involved the organising the weekly lab 






Non – Academic Achievements 
 Louisville Half Marathon        2016 
 Edinburgh Marathon        2012 
 Loch Ness Marathon         2010 
 Students for Kids International Projects (SKIP), Llongwe, Malawi   2008 
 Mount Kilimanjaro, Tanzania       2008 
 50/50 Charity Event, University of Glasgow      2006 
 Certificate of Excellence for Selection in Home International Hill Race   2004 
Giffnock North Athletics Club 
 Level 1 Athletics Coaching Certificate, UK Athletics     2004




I feel it is important to balance a busy work and academic life with social and physical activities. In 
particular, I train and compete regularly in distance running. This has been at school, club, university and 
international levels over the past 10 years. I have broadened my range of running to include both hill 
running such as the Kintyre Way Relay, and long distance running including the Loch Ness Marathon.  
